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1. Abstract
 
1. Abstract 
The (pro)renin  receptor (PRR) is an evolutionary conserved transmembrane receptor that was 
first discovered to bind renin and prorenin. Upon binding, PRR was shown to influence the 
activity of the renin-angiotensin-system (RAS) and to induce MAP kinase signalling. It was 
previously shown that a truncated, transmembrane part of PRR was associated to vacuolar H+-
ATPase (vATPase), a proton pump which is important for acidification. Recently, a new 
function of PRR in the WNT/β-catenin signalling pathway was described. Here, the PRR was 
shown to be an adaptor between WNT receptors and the vATPase. The precise mechanisms 
by which PRR functions, are still elucidative but the PRR is supposed to regulate various 
cellular processes. 
 
Currently, no biochemical characterization or structural analysis is available for PRR. In order 
to gain understanding of the function of the PRR, structural studies were performed with 
several truncated proteins of the extracellular part of the PRR. All PRR proteins (hsPRR170-
303, hsPRR 101-257 or hsPRR 166-257) showed an overall alpha helical folding and did not 
bind renin or prorenin. The oligomeric assembly of the proteins was investigated. The hsPRR 
(101-257) was shown to be in a concentration and pH dependent monomer/oligomer 
equilibrium, whereas hsPRR (166-257) is only present in a monomer/dimer equililibrium. 
These data are the basics for further structural and functional studies.  
 
Additionally, conditional KO animals are an excellent tool to investigate the physiological 
role of the PRR in vivo. As the major mediator of the Wnt/β-catenin signaling pathway, β-
catenin, is crucial for T cell maturation, a conditionel deletion of PRR in T cells was analyzed. 
PRR deletion resulted in a loss of mature T cells. Moreover, a defect in T cell maturation in 
the thymus was determined. Our data showed that PRR is critical for proper T cell 
development and support the hypothesis that PRR contributes to Wnt/β-catenin signaling in T 
cells. 
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2. Introduction 
The (pro)renin receptor (PRR) was first described in 2002 by Nguyen et al as a receptor that 
binds renin or prorenin 1. On the basis of this it was supposed that PRR was a new member of 
the renin angiotensin system (RAS); an important cascade involved in maintaining blood 
pressure homeostasis 2. However, during the last few years it has become clear that the PRR is 
not only involved in blood pressure regulation but also plays a role in WNT signalling, 
vacuolar H+-ATPase mediated acidification and consequently influences early cellular 
development and neuronal function. The precise function of this receptor and how it is 
involved in cellular processes is still unclear.   
 
2.1. The (pro)renin receptor 
PRR is ubiquitously expressed in all cell types. It consists of 350 amino acids with a 
molecular weight of 39 kDa.  The amino terminus contains a short 16 residue signal peptide, 
and a long extracellular domain (amino acids 17 to 303). The intracellular C-terminus covers 
amino acids 327 to 350 with the amino and C-terminus flanking the single transmembrane 
region from amino acids 306-326 (Figure 1).    
 
full-length PRR 
soluble PRR 
1 
SP 
19 350 304 275RKTR278 303 326 
ID ED TM 
327 
associated to vATPase 
18 
Furin cleavage site 
 
Figure 1. Schematic representation of the domains of PRR. 
The PRR consists of a short intracellular (ID), transmembrane (TM), extracellular domain (ED) and 
signalpeptide (SP). A furin cleavage site (275RKTR278) is located in the extracellular domain.  
 
The PRR shows no homology to any known proteins 1. The extracellular domain possesses a 
furin cleavage site (275RKTR278). Furin is a cellular endoprotease that proteolytically 
activates large numbers of proprotein substrates in secretory pathway compartments 3. Upon 
cleavage with furin, a 28 kDa soluble form of the PRR is detectable in the conditioned media 
of cultured cells 4, 5. This soluble PRR fraction is generated intracellularly and is hypothesized 
to be secreted into the blood. Yoshikawa et al have recently described the presence of a 
soluble form of PRR which is secreted into the extracellular space. In contrast, they show that 
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ADAM19 is the protease responsible for cleaving the extracellular region of PRR, instead of 
furin 6. These studies both illustrate the existence of a soluble PRR, but its function remains 
unknown. 
 
It was subsequently realised that PRR was not described for the first time by Nguyen et al 1. 
In 1998, Ludwig et al co-purified a shorter fragment of PRR (8.9 kDa) with the V0 subunit of 
the vacuolar H+-ATPase (vATPase) from chromaffin granule membranes 7. This fragment of 
PRR was later renamed ATP6AP2 (vATPase associated protein 2). Approximately 70 amino 
acids were characterized, consisting of the C-terminal intracellular region, the transmembrane 
region and some additional amino acids from the extracellular domain. A link between PRR 
and vATPase was assumed, and therefore PRR is also known as ATP6AP2 7. Interestingly, 
only a minor amount of the PRR is localized at the plasma membrane, whereas the majority is 
located in intracellular vesicles 8. 
 
The intracellular domain of PRR contains only 24 amino acids and a crystal structure of part 
of this domain was published 9. Fusion of 18 amino acids of this domain to maltose binding 
protein forms a flexible loop. The authors state that these short fragments form a dimer, but 
the dimerization interface remains unknown. Currently, no other structural information is 
available about the PRR. 
 
The PRR is found in a wide variety of species from invertebrates, such as Drosophila, to 
vertebrates, such as Xenopus and up to mammals including human, mouse and rat. 
Interestingly, not all of these species have a functional RAS, which, so far, is found almost 
exclusively in mammals. A gene for renin 10 as well as all other components of the RAS 
(http://www.uniprot.org/) is found in zebrafish, but whether these animals have a functional 
RAS is unclear. In Xenopus, no RAS components except for the angiotensin II type I receptor 
are present, and in Drosophila no RAS components exist. Despite this, PRR demonstrates a 
high evolutionary conservation. Bader and Burckle described that the N-terminal extracellular 
region of PRR is exclusively conserved in vertebrates, whereas the intracellular and 
transmembrane domain display a high amino acid sequence identity among all species 
investigated 11. These authors raise the hypothesis that the PRR might have diverse functions 
due to the different regions of the protein having different evolutionary backgrounds.  They 
propose that the renin binding capacity of the extracellular domain is evolutionary younger, 
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whilst the highly conserved C-terminus has a different function. Additionally, they suggest 
that the PRR might be involved in processes that are independent of renin and prorenin 11.   
 
The only known human disease associated mutation of PRR is described in patients suffering 
from mental retardation and epilepsy. An X-linked mutation in an exonic splice enhancer 
results in the production of a shorter PRR fragment with a deletion of exon 4 and thereby 
reducing full-length PRR levels by around 50% 12. The blood pressure of these patients was 
unchanged. Mutagenesis of the PRR in zebrafish also displays early developmental 
abnormalities. These mutants demonstrate eye and body hypopigmentation, neuronal cell 
death and have early lethality 13. Conventional complete knock-out approaches in mice were 
not successful as no chimeras could be obtained 11, 14. These results all suggest an important 
function for the PRR in early cellular development and also neurogenesis, perhaps in a renin 
and prorenin independent manner.  
  
Details are already known about the function of the PRR in vivo; in particular its role in the 
cardiovascular system 15, its implication on WNT/β-catenin signalling 16 and its link to 
vATPase 7, 17. These described roles of the PRR cover a wide area, including RAS-related and 
RAS-independent functions, and will be explored in the following sections.  
 
2.2. RAS-related functions of PRR 
2.2.1. The renin-angiotensin system (RAS) 
The renin-angiotensin system (RAS) is a hormone cascade controlling and regulating 
cardiovascular, renal and adrenal functions. Blood pressure is increased by the secretion of 
specific hormones, which regulate water and sodium resorption thereby influencing blood 
volume and also inducing the constriction of blood vessels.  The proteolytic enzyme renin is 
produced in juxtaglomerular cells of the kidney. The only known substrate of this protease is 
angiotensinogen. Angiotensinogen is synthesized predominatly in the liver, with minor 
amounts also detectable in the heart, kidney and adipose tissue. Cleavage of angiotensinogen 
by renin is the first step in the RAS cascade. The decapeptide angiotensin I is then cleaved at 
its N-terminus by the angiotensin converting enzyme (ACE), producing the octapeptide 
angiotensin II. Angiotensin II is the intrinsic effector of the RAS and binds to the angiotensin 
II type 1 receptor (AT1R). Angiotensin II induces both directly (via binding to the AT1R) and 
indirectly (via a stimulation of the aldosterone production) increased sodium and water 
reabsorption 18. The angiotensin II/AT1R interaction furthermore mediates the constriction of 
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blood vessels, an increased thirst and salt appetite. All of these actions results in an increase in 
blood pressure (Figure 2). Angiotensin II directly acts on juxtaglomerular cells and is thereby 
able to regulate the secretion of renin by a negative feedback loop 19. The availability and 
activity of renin is the rate limiting step in the RAS. Therefore, this is the most obvious target 
for blood pressure regulation.  
 
 
Figure 2. The renin-angiotensin system (RAS).  
Angiotensinogen is cleaved by renin to produce angiotensin I (AngI), which is further converted to angiotensin II 
(AngII) by the angiotensin converting enzyme (ACE). AngII binds to the angiotensin II type 1 receptor (AT1) 
and increases blood pressure.  
 
The classical circulating RAS is complemented by additional local RAS in diverse tissues. A 
prerequesite for the existence and functionality of a local RAS is the production of the 
individual RAS components in the tissue or alternatively, an uptake of the soluble proteins 
such as renin or angiotensinogen from the circulation. Since the site of expression of renin is 
exclusively in the kidney, a mechanism for the uptake of renin from the circulation into tissue 
is still under investigation. A local RAS is described for the heart, blood vessels, retina and 
kidney 20, 21.  
 
2.2.2. Prorenin und renin 
Renin is a specific aspartyl protease which exclusivly uses angiotensinogen as a substrate. 
Renin folds in predominatly β-sheet conformation, typical for the aspartic proteinase family 
(Figure 3B). The active cleft in the renin molecule contains two catalytically active aspartyl 
residues, aspartic acid 38 and 226 22.   
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Recently, the crystal structure of human angiotensinogen was solved alone (Figure 3 A) and 
in complex with renin (Figure 3 B).  It was shown that the processing of angiotensinogen by 
renin is modulated by a redox switch in angiotensinogen protein. Reduced angiotensinogen 
does not interact with renin that is bound to the PRR, whereas oxidized angiotensinogen is 
converted with a 4-fold increase after binding to renin 23. 
 
A B
 
 
Figure 3. Crystal structure of human angiotensinogen and renin.  
A) Crystal structure of human angiotensinogen alone. The N-terminus contains two unique helices (blue), the 
angiotensin peptide is shown (green) and the renin cleavage site (blue and green balls). B) Human 
angiotensinogen (grey) with renin (light grey) showing the displacement of the angiotensin peptide. The figures 
are taken from Zhou et al. 23. 
 
Prorenin contains an additional 43 N-terminal amino acids. This propeptide is hypothesised to 
cover renins enzymatic cleft and prevent the binding and cleavage of angiotensinogen. No 
structural information for prorenin is available. 
   
Prorenin can be activated proteolytically or non-proteolytically 24. In vivo, proconvertase I 25 
and cathepsin B 26 proteolytically remove the prosegement. This happens exclusively in the 
juxtaglomerular cells. In vitro, activation of prorenin can occur by addition of trypsin or 
plasmin. The reversible, non-proteolytic activation of prorenin occurs under non-
 12
2. Introduction
 
physiological conditions such as low pH (~ pH 3.3) and reduced temperature (~4ºC) 27, 28. 
Under these conditions, the propeptide is thought to no longer cover the active cleft of 
prorenin. 
 
For a long time, it was assumed that prorenin was only the inactive precursor of renin 2, 29. 
However, recent findings suggest that prorenin could have important physiological or 
pathophysiological functions. Under physiological conditions, less than 2% of cirulating 
prorenin is in the active, uncleaved conformation 29. In healthy patients, the plasma 
prorenin:renin ratio is approximately 10 to 1. Prorenin is constitutively secreted into the 
plasma, whereas renin is stored in secretory vesicles and released only after certain stimuli. 
The site of renin expression is only in the juxtaglomerular cells of the kidney, whereas 
prorenin is also produced in the eye, adrenal gland, placenta, testis and ovaries 30. Under 
certain circumstances, the plasma prorenin concentration can rise. During pregnancy, prorenin 
levels are increased and they are used as a marker for the onset of microalbuminuria in 
diabetic patients 31, 32. Microalbuminuria describes the onset of kidney failure, because the 
kidney leaks small amounts of albumin into the urin. Its defined by elevated albumin 
concentrations between 30-300 mg/l urin 33. 
 
For years, it was supposed that a binding partner for renin or prorenin exists. An intracellular 
renin binding protein (Rbp) was found to bind renin and inactivate it 34, but deletion of this 
gene did not result in any change in blood pressure or the RAS 35. In 2001, Saris et al 
discovered that renin and prorenin bind with high affinity to the mannose-6-
phosphate/insulin-like growth factor II receptor 36, 37. After binding, the ligand is internalised 
and degraded. Therefore, this receptor is thought to be solely responsible for renin and 
prorenin clearance, and has no influence on angiotensin I formation 38.  As mentioned above, 
in 2002 Nguyen et al described the binding of renin and prorenin with the PRR 1. 
 
2.2.3. PRR and RAS 
Nguyen showed in 1996 that renin binds specifically to human mesangial cells 39. A 
mesangial cell line without an expression contruct of PRR DNA shows a specific binding to 
renin or prorenin. Binding to PRR increases the activity of renin five-fold and unexpectedly, 
prorenin is also non-proteolytically activated thereby resulting in the production of 
angiotensin I (Figure 4) 1. Batenburg et al showed that renin binds PRR with a kD of 20 nM 
and prorenin with a kD of 7 nM, concluding that prorenin is the endogenous binding partner 
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of PRR 40. PRR is expressed ubiquitously in all cell types. Especially high levels are found in 
the heart, brain, placenta and hematopoetic cells and lower levels in the kidney and liver 1.  
extracellular intracellular 
AOG 
prorenin
Ang I 
PRR 
cell 
membrane 
ERK  
pERK  
Ang II  
 
Figure 4. RAS-dependent function of the PRR.  
The PRR binds renin and prorenin. Upon binding, prorenin is activated non-proteolytically and processes 
angiotensiongen (AOG) to angiotensin I (Ang I). Also, the ERKinase becomes phosphorylated and activates the 
MAP kinase pathway.   
 
Several signal transduction pathways and effector mechanisms are triggered in an angiotensin 
II independent manner upon binding of renin or prorenin to the PRR. To analyze PRR 
mediated signal transduction, cells were pretreated with AT1R blockers to exclude 
angiotensin II induced effects, and then stimulated with renin or prorenin. These experiments 
show that the mitogen activated protein kinase (MAPK), Erk1/2, is activated in vitro in 
monocytes 41, mesangial cells 1, 42, vascular smooth muscle cells 43-45 and endothelial cells 46 
after stimulation with renin or prorenin. This stimulation induced an increase in the 
transforming growth factor β 42, 47, 48, which in turn stimulated the expression of the 
profibrotic genes plasminogen activator inhibitor 1 42, 44, 47, fibronectin 42, collagen I 42 and 
inflammatory associated proteins such as cyclooxygenase 2 49, interleukin 1 50, 51 and tumor 
necrosis factor α 51. Interaction with renin or prorenin also induced cell proliferation in 
mesangial cells 1. Another study shows in cardiomyoctes, prorenin induced angiotensin II 
independent activation of the p38 MAP kinase. Thus, a role for the PRR in this signal 
transduction pathway is likely 52. A yeast two-hybrid screen identified the transcription factor 
promyelotic zincfinger (PLZF) as a new binding partner for the PRR. After activation of the 
PRR by renin, PRR was shown to interact with PLZF which then translocates into the nucleus 
and inhibits the expression of PRR 53, 54.  
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It is hypothesized that PRR is directly involved in pathology because of its involvement in 
several signalling pathways resulting in the expression of inflammatory and fibrotic genes. 
Additionally, a polymorphism in the PRR gene was shown to be associated with blood 
pressure in Japanese men 55. This was also confirmed by another group studying a Caucasian 
cohort, who has an identical phenotype 55, 56. Also a transgenic rat overexpressing the PRR 
develops elevated blood pressure levels after 6 month of age 57. Another group reported 
glomerulosclerosis in a similar animal model 58. Both animal models had a moderately mild 
phenotype with a late onset arguing for a rather marginal role of the PRR in cardiovascular 
pathology. 
 
Since its discovery, discussion has centered on the development of PRR inhibitors which 
would block the angiotensin II mediated effects of PRR and therefore be beneficial 
antihypertensive therapies. Ichihara et al designed a decapeptide inhibitor (handle region 
peptide, HRP) which mimicked some of the amino acids of the prosegment of prorenin called 
the “handle” region. This region was shown to be important for the non-proteolytic activation 
of prorenin 59. Since prorenin becomes activated by binding to the PRR, this peptide is 
proposed to competitivly inhibit the binding of prorenin to the PRR. However, several 
conflicting studies arose with this putative PRR inhibitor. In diabetic animals, HRP prevents 
the formation of glomerulosclerosis 51. HRP treatment in spontanous hypertensive rats results 
in reduced cardiac fibrosis, proteinuria and glomerulosclerosis 59, 60. Also in diabetic AT1R 
KO mice, HRP prevents the formation of glomerulosclerosis 61. Based on these results, it is 
proposed that PRR has pathologic actions via an angiotensin II independent pathways. 
Beneficial effects of HRP treatment are also shown in pathologies such as retinal 
neovascularization and ocular inflammation 62. For all of these studies, only prorenin is 
considered as a binding partner for the PRR. In contrast to these findings, several other 
publications could not confirm the beneficial effects of HRP. Susic et al found in their model 
of spontanous hypertensive rats that HRP does not ameloriate cardiac hypertrophy 63. Several 
other animal models also do not confirm the observed beneficial effects of HRP. In double 
transgenic animals overexpressing renin and angiotensinogen 43, as well as in Goldblatt 
hypertensive animals 64, no ameliorated cardiac or renal factors are observed upon treatment 
with HRP. These studies suggest that the efficiency of HRP as a therapeutic compound for 
renovascular damage needs further examination. So far no other inhibitor for the PRR has 
been described. Without further knowledge about the detailed cellular function of PRR it 
remains controversial as to whether PRR should be seen as a drug target. The angiotensin II 
 15
2. Introduction
 
independent functions of the PRR are still not completely understood, and the consequences 
of blocking them are not clear. Another aspect is the direct inhibition of renin, as this will 
result in higher renin levels. Renin might not longer be able to process angiotensinogen, but 
an interaction with the receptor is likely and the induction of its signal transduction 65. 
 
2.3. RAS-independent functions of the PRR 
2.3.1. vacuolar H+-ATPase (vATPase) 
As previously mentioned, when PRR was first discovered it was found to be associated with 
the vATPase 7. The vATPase is an ATP-dependent proton pump. Its main function is the 
regulation of pH in intracellular compartments and extracellular fluids, which is essential for a 
variety of cellular processes 66. 
 
2.3.1.1. Structure of the vATPase 
vATPase is structurally and mechanistically related to F-ATPase, and even more closely to 
archaebacterial ATPase. vATPase is a rotary proton pump which hydrolyses ATP. In contrast 
to F-ATPase, vATPase is not able to synthesise ATP 67. vATPase is divided into two 
domains. It consists of a cytoplasmic 650 kDa V1 domain where ATP hydrolysis occurs and a 
260 kDa membrane V0 domain responsible for proton translocation (see Figure 5) 66, 68. All 
together, vATPase is composed of 14 protein subunits. Additionally, different isoforms of 
these subunits are described for several tissues and cellular locations, further increasing the 
complexity of this pump. The V1 complex contains 8 subunits: A, B, C, D, E, F, G, H. Three 
copies of each of the A and B subunits are present, which form an alternating hexamer with 
three catalytic sites in the A subunit for ATP hydrolysis, and three nucleotide binding sites at 
the AB interface. Surrounding the AB ring are two copies of the G and E subunits, which form 
heterodimers.  Further present in the complex are 1 or 2 copies of the H subunit, and a single 
copy of all other subunits. Functionally, a peripheral stalk, composed of the C, E, G, H 
subunits, and a central stalk, composed of the D and F, subunits are defined. The central stalk 
provides the energy to the rotation necessary for proton transport, whereas the peripheral stalk 
is hypothesized to prevent rotation of the AB hexamer. The peripheral stalk, the AB complex, 
and subunits a and e of the V0 domain, form the stationary part of vATPase called the “stator”.  
 
The V0 domain consists of the subunits a, c, c´, c´´, d and e. Subunit a has eight or nine 
transmembrane regions with one buried arginine residue that connects the V1 and V0 complex 
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and is absolutely necessary for proton translocation. The c, c´ and c´´ subunits form the so-
called proteolipid ring. These highly hydrophobic subunits all possess a single buried 
glutamate residue, which is also important for proton transport.  The d subunit sits atop of the 
proteolipid ring and connects the V0 domain with the central stalk of the V1 domain. The 
function of the highly hydrophobic e subunit has so far not been described 68. 
 
 
 
Figure 5. Schematic representation of the structure of vATPase.  
vATPase is composed of the V1 (orange and green) and the V0 domain (blue) and its subunits (A-H (V1) and a-e 
(V0)). The V1 domain is responsible for ATP hydrolysis, while the V0 domain translocates the protons across the 
membrane.  For details see text. The figure is taken from Forgac 68. 
The correct assembly and targeting of vATPase is critical for its function in certain tissues and 
cellular compartments. The V1 domain is able to self-assemble, whereas the V0 domain 
requires the support of several endoplasmatic reticulum assembly factors such as VMA 
(vacuolar membrane ATPase activity) 21, VMA 12, VMA 22 and Pkr169-71. The targeting of 
vATPase to its site of activity is mediated by several isoforms.  Four isoforms of the a subunit 
have been described, which all differ in the cell type in which they are expressed and the 
cellular location in which they function. Multiple isoforms of the same subunit are also 
possible in one cell 68, 72. For example, the a1 subunit is found in presynaptic nerves, in 
synaptic vesicles and on the plasma membrane 73. The a2 subunit is expressed in renal 
proximal tubule cells in the apical endosomes 74. In contrast, the a3 subunit is localised on the 
plasma membrane of osteoclasts 75, whereas a4 is located in the apical membrane of renal 
intercalated cells 76. Most of the other V0 subunits have two isoforms, where one isoform is 
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ubiquitously expressed and the second isoform is only expressed in a specific cell type or 
tissue 68.  PRR is not thought to be directly involved in the formation of vATPase complex, 
but is associated to the V0 domain. Therefore, PRR might play role in assembly of the V0 
domain. 
2.3.1.2.  Proton transport of the vATPase  
Protons are translocated after ATP hydrolysis via an active transport mechanism, through the 
rotation of the proteolipid ring, subunits D, F and d 77. Protons enter from the cytoplasmic 
side of the membrane through a hemi-channel of subunit a, and protonate the buried 
glutamate in the c, c´ or c´´ subunit. Following ATP hydrolysis, the proteolipid and accessory 
subunits rotate, thereby displacing the protons. The protonated glutamate then interacts with 
the buried arginine in the a subunit 66. This arginine becomes protonated and releases the 
proton into the lumen of the vesicular compartment or the extracellular fluid 78. The 
stoichiometry for this process is between 1:2 and 1:3. Three, since there are three ATP 
binding sites in the AB hexamer and 6-10 protonable sites in the proteolipid, depending on the 
amount of proteolipids in the ring 68. 
 
Bafilomycin and concanamycin are inhibitors for vATPase and are proposed to block proton 
transport by circumventing the helical rotation around their own axes of the proteolipids. This 
helical swivelling is important for the rotation and the proton transport of the proteolipid ring 
79-82. 
 
2.3.1.3. Regulation of vATPase activity 
Since pH is crucial for many cellular processes, vATPase activity is highly regulated. Several 
mechanisms are described for the regulation of vATPase activity. One mechanism is the 
reversible dissociation of the domains V1 and V0. This mechanism is best understood in yeast 
and insect cells, but also occurs in mammalian cells 68. In yeast, it was shown that after 
depletion of glucose, which consequently resulted in a reduction of ATP consumption, the 
two domains of vATPase dissociated 83. This process is reversible, but dissociation and 
assembly are regulated differently. Assembly in yeast requires a protein complex called 
RAVE 84, whereas dissociation is not dependent on this complex.  The mechanism for the 
reversible dissociation is not fully understood, but it is hypothesized that the non-homologous 
region of the A subunit plays a role in dissociation 85. Also, the RAS/cAMP/protein kinase A 
pathway has been described to be involved in the dissociation of vATPase 86.  A role for PRR 
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in assembly or dissociation of vATPase is possible. Because of its transmembrane 
localization, an interaction with the V0 domain appears feasible. Thus, regulation of vATPase 
activity could be mediated via an interaction between the V0 domain and the PRR. The first 
evidence for an involvement of PRR in vATPase assembly and function came from Kinouchi 
et al. They showed that deletion of the PRR results in a downregulation of the V0 subunits and 
affect the stability and assembly of the V0 subunits, thereby compromising vesicular 
acidification 87. 
 
Besides reversible dissociation, another regulatory mechanism of vATPase activity is the 
endocytosis or exocytosis of vATPase at the plasma membrane. In this case, vATPase is 
stored in vesicles close to the plasma membrane in renal epithelial cells and is transported to 
the membrane upon induction by a glucose stimulus. The complex is internalised and 
trafficked to intracellular storage compartments if proton transport is reduced 88.   
 
A third hypothesized mechanism for the regulation of vATPase activity is the 
increase/decrease of the coupling efficiency of ATP hydrolysis and proton translocation. This 
mechanism is controlled by the different a subunit isoforms.  Different yeast homologs for the 
a subunit showed altered coupling efficiency suggesting a tighter coupling of proton transport 
and ATP hydrolysis 72. A special mechanism to regulate the activity of vATPase is the 
formation of a reversible disulfide bond in the subunit a, causing a disruption of the catalytic 
function of the ATPase 89. 
 
A tight regulation of vATPase activity is important for cellular function and is achieved by 
these various processes. A role for the PRR in these mechanisms is possible, but needs further 
investigation.  
 
2.3.2. PRR and vATPase 
It has been shown that PRR is associated to vATPase 7. Another link between PRR and 
vATPase was shown by Advani et al, where PRR was demonstrated to co-localize with the B 
subunit of vATPase in the kidney 90. Additionally, Cruciat et al showed that PRR co-
immunoprecipitated with transmembrane subunits of vATPase 16. All of these effects were 
first shown in vitro, until recently where support for a link between PRR and vATPase came 
from in vivo studies. The first conditional knock-out of PRR in cardiomyocytes resulted in 
lethal heart failure accompanied with impaired autophagic degradation 87. The authors explain 
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these phenomena by the defective acidification of intracellular compartments, which is 
necessary for protein degradation. They showed that malfunction of this acidification was due 
to a disordered assembly of vATPase; evidenced by deletion of PRR reducing protein levels 
of subunits of transmembrane vATPase 87. Furthermore, conditional KO of PRR in podocytes 
also caused a defect in protein degradation and autophagy 91, 92. Podocytes form the main 
filtration barrier in the kidney and deletion of PRR in this cell type resulted in kidney failure 
and early lethality. Additionally, similar to the phenotype observed in cardiomyocytes, the 
authors observed a block in podocyte lysosome processing, which they propose could be due 
to defective vATPase function and impaired acidification 91. Another group described the 
same podocyte model with a similar phenotype. They confirmed again that deletion of PRR 
suppressed expression of the c subunit of the V0 domain of vATPase, resulting in 
deacidification of intracellular vesicles 92. All of these studies point towards PRR having an 
important role in the function and regulation of vATPase in vivo. 
 
2.3.3.  Physiological and pathophysiological function of the vATPase 
vATPase is involved in a variety of cellular processes where acidification is necessary. 
Depending on its cellular localization it is involved in different functions. For example, 
vATPase is found in cellular compartments such as endosomes, lysosomes, Golgi-derived 
vesicles, clathrin-coated vesicles, secretory vesicles and the central vacuoles of plants and 
fungi. In these compartments, vATPase is engaged with protein trafficking including 
processes such as clathrin-mediated endocytosis, receptor recycling, lysosomal degradation 
and secretion. In clathrin-mediated endocytosis, ligand-receptor complexes are clustered in 
clathrin-coated pits which then bud off from the plasma membrane as clathrin-coated vesicles 
and form early- or sorting-endosomes. Sorting endosomes are then acidified by vATPase and 
the internalised ligand-receptor complex dissociates. The receptor is then shuttled back to the 
cell surface and the ligand is further trafficked to the lysosome. In lysosomes, proteases are 
only active at low pH and thus acidification by vATPase is essential for the degradation of 
proteins 68. Not only for protein degradation, but also for the processing of proteins vATPase 
is necessary. In secretory vesicles, vATPase is essential for the activation of proteases at low 
pH cleaving prohormones, such as in pancreatic beta cells, where proinsulin is converted to 
insulin 93. Additionally, vATPases provide the membrane potential or pH gradient required to 
drive the transport of neurotransmitters in secretory vesicles 94. Previously, it was shown that 
PRR is expressed in the brain and plays a role in the neural control of cardiovascular 
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functions 95. Besides the acidification in intracellular compartments, the vATPase is also 
involved in development in Xenopus embryos 96.  
 
vATPase is also found on the plasma membrane of a variety of cells. Mutations in subunits of 
vATPase are involved in several pathophysiologies. In particular, cell surface vATPase in the 
kidney is important for several processes. Alpha-intercalated cells in the kidney have a large 
amount of vATPases in their apical membrane, which acts to secrete protons into the lumen of 
the distal tubule and collecting duct. This mechanism is important for the acid/base 
homeostasis of the urine 97, and a mutation in the B subunit of the vATPase results in an 
inherited form of distal renal tubule acidosis 98. Osteoclasts are another cell type in which 
vATPase has an important role. At the plasma membrane, vATPase creates an acidic pH 
necessary for the activity of digestive enzymes that degrade the bone. A mutation in vATPase 
subunit a3 in osteoclasts results in osteopetrosis 99. This disease is characterized by thickening 
of the bone, due to malfunctioning of the bone degradation machinery. Interestingly, this 
same mutation in the a3 subunit additionally results in a decreased insulin secretion in beta 
cells in the pancreas 75.  vATPase is also critical for sperm maturation in the vas deferens. 
Here, the epididymal clear cells secrete protons into the lumen of the epididymus to generate 
an acidic pH required for the development and maintenance of sperm 100. Additionally, 
vATPase plays a crucial role for maintaining the homeostasis of neutrophils and macrophages 
when they are recruited to sites of inflammation. At these sites there is often an acidic pH, and 
thus, these immune cells require a functional vATPase at the plasma membrane in order to 
maintain their neutral intracellular pH 101. vATPase also influences angiogenesis of 
endothelial cells, especially in migration, invasion and tumor metastasis. In the case of tumor 
cells, vATPase acidifies the extracellular surrounding, thereby promoting invasion by 
providing the low pH required for cathepsins to digest the extracellular matrix 102. These 
studies highlight that vATPase is important for several pathophysiological processes.  
 
Besides the above described diseases associated with vATPase, a role for vATPase in 
bacterial and viral infections is also known. Several viruses and toxins enter the cell with the 
help of vATPase. One example is the influenza virus, which is able to infect the cell due to 
the low pH in the endocytosed viral vesicles which facilitates fusion of the viral and 
endosomal membranes, resulting in the release of viral RNA into the host cell 103. The low pH 
in intracellular vesicles additionally aids the entry of bacterial toxins such as anthrax or 
diphtheria into the cell 104. vATPases are also hypothesized to play a role in infection by HIV. 
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In this case, the virus enters the cell via the CD4 receptor on T cells, within endosomes. 
Acidification by vATPase is crucial for the intracellular release of the virus. Additionally, the 
H subunit of vATPase has been shown to interact with the virus protein NEF and regulate 
CD4 internalization so as to prevent multiple infections 105.  
 
Taken together, these facts show that vATPase is involved in several diseases and is also 
crucial for physiological processes. This makes vATPase an important complex for the 
maintenance of cellular function. Therefore, the function of the PRR and its importance for 
vATPase, in vitro and in vivo, should be elucidated further. 
 
2.3.4. WNT/β-catenin pathway 
A recent publication described PRR as an important protein involved in WNT/β-catenin 
signalling 17. The WNT/β-catenin canonical signalling pathway has an essential role in cell 
proliferation, stem cell maintenance, cell fate decision, organized cell movements and the 
establishment of tissue polarity. It is frequently deregulated in human cancer and degenerative 
disease 106. Besides the canonical WNT pathway, non-canonical WNT pathways exist, among 
them the planar cell polarity pathway 107.   
 
The canonical WNT pathway depends on the presence of WNT (see Figure 6). WNT is a 
secreted signalling molecule and binds to its cell surface receptor Frizzled. Upon binding to 
Frizzled, the complex interacts with the membrane-bound co-receptor LRP6 (low-density 
lipoprotein receptor-related protein 6). In the next step, Dishevelled is recruited to the receptor 
complex and becomes activated. Dishevelled is another key component of the canonical WNT 
pathway and inhibits the destruction complex.  This destruction complex is composed of the 
proteins axin, glycogen synthase kinase 3 (GSK3), adenomatous polyposis coli (APC) and 
casein kinase 1 (CK1). The destruction complex promotes the proteolytic degradation of β-
catenin. Dishevelled destroys this complex, but the mechanism for this is not clear. In turn, β-
catenin accumulates in the cytoplasm and translocates into the nucleus where it interacts with 
the transcription factor family TCF/LEF to induce gene expression. After interaction of β-
catenin with TCF, groucho dissociates and target gene transcription starts. In the absence of 
WNT, β-catenin is complexed with the destruction complex, where it is phosphorylated by 
GSK3 which then targets it to the β-TrCP E3 ligase. This complex promotes the 
ubiquitinylation of β-catenin, subsequently resulting in the proteolytic degradation of β-
catenin by the proteasome 107, 108.  
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Figure 6. Schematic representation of the canonical WNT/β-catenin pathway.  
In the absence of Wnt signal, β-catenin is recruited into the APC/Axin/GSK3/CKI complex, and is 
phosphorylated by GSK3. Phosporylated β-catenin binds to β–Trcp E3 ligase of the proteosome machinery and 
is targeted for degradation. Wnt binds to its frizzled Fz receptor and LRP5/6 co-receptor and activates 
dishevelled (Dvl), leading to the inhibition of APC/Axin/GSK3 mediated β-catenin degradation. Stabilized β-
catenin forms a transcriptional complex with LEF/TCF and activates downstream targets. The figure is taken 
from Cardigan and Pfeiffer 108. 
 
There are also several non-canonical pathways, such as the planar cell polarity (PCP) 
pathway. The biggest difference between the non-canonical and the canonical-pathways is the 
independence of β-catenin.  The PCP pathway is best understood in Drosophila and only a 
little is know about these pathways in mammalian cells 106. Frizzled and dishevelled form a 
complex that binds and activates small Rho GTPases and JNK (c-Jun N-terminale kinase) 106.  
In this thesis, I will focus on the canonical-WNT pathway. 
 
2.3.5. PRR and WNT signalling  
A new function of PRR was proposed by Cruciat et al in 2010, where they describe PRR as a 
component of the WNT receptor complex 17.  They show that PRR binds to WNT receptors 
Frizzled and LRP6 and hypothesize that PRR in combination with vATPase, influences LRP6 
phosphorylation and activation. This phosphorylation process may only occur under acidic 
conditions mediated by vATPase. Additionally, they describe a PRR knock down in Xenopus 
that results in body morphogenesis and pigmentation defects displaying a similar phenotype 
as already described for zebrafish.  All these functions are renin-independent 17.   
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In the same year, two other publications confirmed the importance of PRR for non-canonical 
WNT signalling.  They both show in Drosophila that PRR interacts with Frizzled 109, 110. The 
authors hypothesize that the complex of vATPase and PRR, contributes to the function and 
signalling of Frizzled and thereby mediates non-canonical WNT (PCP) signalling. They also 
report that a knock down of PRR in Xenopus results in a defective PCP signalling phenotype, 
similar to previously published ones 109.  Thus, PRR is not only involved in the canonical 
WNT pathway described by Cruciat et al 17, but also plays a role in the non-canonical WNT 
pathway. It has been hypothesized that PRR is a conserved modulator of both non-canonical 
and canonical WNT pathways bridging the WNT receptors with vATPase 17, 109. 
 
2.3.6. WNT/β-catenin signalling in development and disease 
The canonical WNT pathway is highly conserved in evolution and is a fundamental signalling 
pathway in all species 111. The impact of WNT signalling on development and disease is 
described in the following.  
 
The use of gain-of-function and loss-of-function mutations of WNT components in animal 
models have helped to obtain insight into the diverse functions of the WNT pathway in 
development 112. The WNT pathway has an enormous role in stem cell fate and proliferation 
108. It has also been shown that WNT signalling is critical for the proliferation of intestinal 
epithelial cells 113 and hair follicle stem cells 114. WNT signalling also controls differentiation 
of mesenchymal stromal stem cells and regulates the self-renewal of hematopoietic stem cells 
112. For example a gain-of-function mutation that results in constitutive active β-catenin in 
hematopoetic precursors results in impaired self renewal of these cells 115, 116. 
 
In terms of disease, the WNT pathway is implicated in cancer progession. A large number of 
mutations in WNT pathway related genes are associated with leukaemia, colon cancer and a 
variety of other cancers 111. APC is a tumour suppressor gene and allelic mutations, resulting 
in loss of both functional alleles, is present in almost 80 % of all sporadic colorectal cancers. 
Mutation of APC results in an over-activation of the canonical WNT pathway, resulting in β-
catenin being no longer bound to the degradation complex and thereby inducing the 
uncontrolled proliferation of intestinal epithelial cells 117. Some colon cancers are linked to a 
loss of function mutation of Axin, which in turn are correlated to hepatocellular carcinomas 
111.   
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A deregulated WNT pathway is involved in several additional diseases. Skeletal disorders and 
bone formation are linked to deregulated WNT components. Expression of gain-of-function 
LRP5 in mice results in high bone density and elevated numbers of active osteoblasts, while 
loss-of-function of LRP5 leads to reduced bone mass in animal models 111. Interestingly, 
vATPase is also involved in bone formation; mutations in vATPase subunit a3 in osteoclasts 
results in osteopetrosis 99.  Disturbed WNT/β-catenin signalling is as well involved in 
neuronal disorders, like Alzheimers disease and, moreover, in wound healing and 
cardiovascular disease 107. Mice models with defective WNT signalling are more prone to 
infarct rupture after induction of myocardial infarction and neovascularisation of the infarct 
area is influenced 118. The contribution of PRR to these diseases that are associated with a 
deregulated WNT/ β-catenin pathway is yet to be determined. 
 
2.4. T cells 
T cells are a specialised type of immune cell which play a central role in cell mediated 
immunity. Their main function is the recognition of intracellular pathogens and activation of 
B cells 119. To become a functional T cell, they undergo several steps of maturation in the 
thymus for which the canonical WNT signalling pathway is essential 120. PRR is ubiquitously 
expressed and shows a high level of gene expression in hematopoietic tissue (personal 
communication, M. Andrade, MDC, Berlin, Germany). As described above, PRR is proposed 
to be an adaptor between the WNT receptors and vATPase, and thus, might be important in T 
cell maturation 17.  
 
2.4.1. T cell function  
The immune system is composed of several cell types originating from pluripotent 
hematopoetic stem cells from the bone marrow. These hematopoetic stem cells separate into 
common myeloid progenitors that give rise to granulocytes, macrophages, dendritic cells and 
erythrocytes and into common lymphoid progenitors. The common lymphoid progenitors give  
rise to B and T cells, which are both components of the adaptive immunity, and to natural 
killer cells 119.  
 
T cells are defined by their maturation in the thymus and their expression of a T cell receptor 
(TCR).  The TCR is a cell surface receptor responsible for the recognition of antigens and the 
activation of T cells. The TCR is a heterodimer consisting of a α- and β-chain or a γ- and δ-
chain. The γδ T cells are engaged in early and late immune responses, and function as effector 
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cells and immune regulators. Because γδ T cells are the first T lymphocytes to arise in 
ontogeny, it seems likely that they play an important role in immune protection early in 
development 121.  
 
The majority of T cells express the CD3 TCR that is composed of α- and β-chains, which play 
a major role in cell-mediated immunity. These T lymphocytes are further separated into T 
helper cells, cytotoxic T cells and regulatory T cells. T helper cells express the CD4 protein 
on their cell surface, whereas cytotoxic T cells express CD8 on their surface and therefore 
they are known as CD4+ and CD8+ T cells, respectively. CD4 and CD8 are co-receptors for 
the TCR that are required to bind to the major histocompatibility complex (MHC) present on 
all antigen presenting cells, such as dendritic cells or macrophages. CD4 binds to MHC class 
II, whilst CD8 interacts with MHC class I. This interaction is important for antigen 
recognition and T cell response 119.  For activation of T cells, signalling via the TCR MHC 
complex is essential, but also co-stimulatory signals are required. The best known signal is the 
CD28-mediated co-stimulus. In response to this, T cells clonally expand and become 
activated 122. CD8+ T cells are responsible for the killing of pathogen infected cells. The CD8+ 
cells induce formation of a pore and activate apoptotic pathways. CD4+ T cells are not 
directly involved in cell apoptosis, instead they assist to activate CD8+ T cells or 
macrophages, and effect the maturation of B cells 119. Upon activation, the CD4+ T cells 
differentiate into several subtypes expressing diverse cytokines, thereby modulating the 
immune response. For example, Interleukin 12 induces the development of Th1 cells that 
secrete interferon γ and support the cellular immune response. In contrast interleukin 4 
stimulates the expansion of Th2 cells affecting the humoral immune response 123. Th17 cell 
development is triggered by the presence of TGF β, interleukin 6 and 21. These cells are 
characterized by the expression of interleukin 17. Th17 cells are important in clearing 
pathogens during host defence reactions and inducing tissue inflammation in autoimmune 
disease 124, 125.  The last T cell subtype is regulatory T cells. These are induced by TGF β and 
are supposed to have suppressor and regulatory functions for the immune system 126. Most of 
these cells die within 1 or 2 weeks after activation, and only a small subset survives as 
effector memory T cells or central memory T cells 123.   
 
 26
2. Introduction
 
2.4.2. T cell development 
For the existence and function of T cells, their maturation process is crucial. The WNT/β-
catenin pathway plays a key role in their development and thus the role of the PRR in this 
process should be analyzed closer.  
 
T cell maturation is a highly regulated and complex procedure. Initially, common lymphoid 
progenitors migrate to the thymus. They do not express the TCR or the co-receptor CD4 and 
CD8 and are therefore called double negative (DN; CD4-/CD8-) cells. These DN cells are 
further characterized by the expression of the two surface markers CD44 and CD25, 
corresponding to the α-chain of the interleukin-2 receptor. In the first DN stage, the cells are 
negative for CD25 and positive for CD44 and are also referred to as DN1 (CD25-/CD44+) 
(Figure 7). During the next maturation step (DN2; CD25+/CD44+) the cells downregulate the 
hematopoetic stem cell marker cKIT and upregulate CD25. With this, they lose their potential 
to form other cells, such as B cells and natural killer cells and are committed to the T cell 
lineage 127. Until this point the cells are moderately proliferating, whilst during the DN3 
(CD25+/CD44-) stage they stop proliferation and downregulate CD44. During the following 
rearrangement of the β-chain, the TCR gene is genetically recombined to recognize different 
antigens.  Cells which successfully rearranged their β-chain, present the pre-TCR on their 
surface; cells that do not rearrange successfully undergo apoptosis. The pre-TCR is composed 
of a β-chain and a non-rearranged α-chain. This point is the first important stage for T cell 
maturation called the “β-selection checkpoint” 128, 129. β-catenin deletion results in a 
developmental block at the DN3 stage to DN4, pointing towards an important role of WNT/ 
β-catenin signalling in the β-selection checkpoint 120. When cells further proceed with their 
next maturation process (DN4; CD25-/CD44-), they downregulate CD25 and start to express 
the CD4 and CD8 co-receptors, therefore becoming double positive cells (DP; CD4+/CD8+).  
More then 90 % of the cells die at this stage during a positive selection process.  Only cells 
that moderately bind to MHC class I or II complexes are chosen, whereas non-functional T 
cells are eliminated by “death by neglect”, because they do not obtain important signals for 
their further survival. The surviving cells start to express high levels of the TCR with a 
rearranged TCR α-chain, whilst the pre-TCR is downregulated. Between 5-10 % of the 
remaining cells are negatively selected because they bind to self antigens and undergo 
apoptosis. Only 2 % of T cells survive these selection rounds and transit from a DP cell, to a 
single positive (SP) mature CD4+ (helper) or CD8+ (cytotoxic) cells. These cells then move 
from the thymus to the blood stream. 128. The T cell repertoire is established during early 
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years, as the thymus shrinks during adolescence. However, T cell production remains 
continuous 127 
 
.  
Figure 7. Overall scheme of T cell development in the thymus. 
The hematopoetic precursors migrate from the bone marrow to the thymus. The double negative (DN) cells are 
characterized by the absence of CD4-/CD8-. These cells can be further subdivided into DN1-DN4 cells 
characterized by the expression of CD25 and CD44. Thereafter DN cells start to express the CD4+/CD8+ antigen 
(DP) and finally develop into single positive CD4+ or CD8+ cells. For details see text. The figure is adapted from 
Zúñiga-Pflücker 130 
 
2.4.3. T cells and PRR 
A role for PRR in T cells has not been described before, but as WNT/β-catenin signalling and 
vATPase are involved in T cell function and development a role for PRR is likely. 
 
β-catenin is the central mediator of WNT signalling and a conditional deletion in T cells 
results in an impaired T cell development 120. The authors showed that the amount of T cells 
was drastically reduced in lymphoid tissues and the circulation, while B cells were not 
affected.  The lack of β-catenin did not result in an increased apoptosis or in a dramatic 
changed proliferation rate, thus concluding that the maturation in the thymus is affected.  A 
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block in development was shown by analyzing the thymocytes. The pre-TCR signalling seems 
to be dependent on functional WNT signalling 120.    
 
Another publication implicates that vATPase also plays an important role for T cell 
development. Pua et al published that autophagy is critical for lymphocyte development and 
function and suggest an essential role for survival and proliferation. Autophagy is an 
intracellular degradation process depending on acidification. Mice that are deficient for ATG5 
had reduced numbers of T cells with a dramatically increased number of dead cells and a 
proliferation defect 131. vATPase was shown to play a role in the infection of HIV. It helps the 
virus to enter the CD4+ T cell and prevents multiple infections of the same cell 105, 132  
Acidification of the lytic granules of the cytotoxic T cell is dependent on vATPase and 
therefore necessary for their function 133. All these observations point to an important role of 
vATPase and WNT/β-catenin signalling for T cell function and maturation and therefore 
imply a fundamental role for PRR for T cells. Additionally T cell subtypes are important to 
cardiovascular function and target-organ damage 134 .  
 
A better understanding of the function of the PRR for these cells would give insight into T 
cell regulation. Additionally, this cKO model would provide knowledge about the in vivo 
implication of PRR for vATPase and WNT/β-catenin pathway.  
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2.5. Objectives of the work 
 
The aim of this thesis was to characterize the PRR. This characterization might help in the 
future to obtain a better understanding of the role of the PRR for the RAS, WNT/β-catenin 
pathway and the vATPase, both in vitro and in vivo.  
 
No structural data is available for the soluble region of PRR.  Therefore, the first aim of my 
thesis was to obtain structural information by protein X-ray crystallography of the soluble 
region of PRR. With the help of structural data, additional information about possible binding 
sites to renin or prorenin or other interaction partners could be analyzed and would give 
insights into the function of the soluble region of PRR. 
 
Specific aims therefore were to find soluble, truncated proteins of PRR that could be purified 
in high amounts and quality in an E.coli expression system. These constructs were then 
analyzed for their secondary structure to obtain information about their folding. Next, binding 
to renin or prorenin of these constructs was analyzed. In addition these PRR proteins were 
analyzed for their oligomerization behaviour. All constructs were used for crystallization 
trials.   
 
The second aim of my thesis was to analyse the role of the PRR in an in vivo system, using a 
conditional knockout approach. The hypothesis tested that the deletion of PRR in T cells 
would result in phenotype similar to that of a β-catenin knockout, displaying a maturation 
defect at the DN3 to DN4 cell stage. With this, the possible link of PRR to WNT/β-catenin 
pathway should be analyzed to understand the function of the PRR. 
 
In this project it was analyzed if PRR deletion results in a decrease of T cells in peripheral 
lymphoid tissue.  Furthermore it was determined what kind of T cells, CD4+ or CD8+ cells, 
are reduced in this cKO model. To explain the reduction of T cell it was further analyzed if 
this is due to a developmental defect. For that reason, T cells were examined during their 
maturation process in the thymus. The proportion of typical cellular stages of thymus 
maturation, double negative, double positive and single positive CD4+ or CD8+ T cells, was 
determined. The double negative cell subset was further analyzed for the proportion of DN3 
and DN4 cells to draw conclusion for possible blocks in the distinct developmental steps.  
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3.1. Materials 
3.1.1. Chemicals 
Chemicals were obtained from the following companies: Karl Roth GmbG & Co. KG 
(Karlsruhe, Germany), Jena Bioscience (Jena, Germany), Merck KGaA (Darmstadt, 
Germany),  Sigma-Aldrich GmbH (Hannover, Germany), Amersham-Pharmacia (Freiburg, 
Germany), Qiagen (Hilden,  Germany), GE Healthcare  (Munich, Germany), BD Bioscience 
(Heidelberg, Germany)  and Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). 
 
3.1.2. Enzymes 
KOD DNA Polymerase Novagen (Darmstadt, Germany) 
PFU DNA Polymerase  Roboklon (Berlin, Germany)  
T4 DNA Polymerase New England Biolabs (Frankfurt a.M., Germany)
DNase I Roche (Mannheim, Germany) 
Restriction Nucleases  
(BamHI, XhoI, EcoRI, NotI, DpnI) 
New England Biolabs (Frankfurt a.M., Germany) 
 
Prescission Protease GE Healthcare (Munich, Germany) 
Trypsin, Chymotrypsin, Thermolysin, Subtilisin Sigma Aldrich (Hannover, Germany) 
Superscript III Reverse Transkriptase Invitrogen (Darmstadt, Germany) 
Proteinase K Roth GmbG & Co. KG (Karlsruhe, Germany) 
 
3.1.3. Clones 
cDNA clones for the human (Homo sapiens), mouse (Mus musculus), zebrafish (Danio rerio) 
and frog (Xenopus laevis) PRR were purchased from imaGenes (Berlin, Germany). 
 
3.1.4. Kits and standards 
Kits  
QIAgen Plasmid Purification (Mini) Kit Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit Qiagen (Hilden, Germany) 
Rneasy Kit Qiagen (Hilden, Germany) 
DNAse Digest  Qiagen (Hilden, Germany) 
Superscript III cDNA Synthesis Kit       Invitrogen (Darmstadt, Germany) 
NuPageNovex Bis Tris precast gel system   Invitrogen (Darmstadt, Germany) 
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Kits  
TaqMan® Fast Universal PCR Master Mix Applied Biosystems (Carlsbad, USA) 
CytoFix/CytoPerm Solution Kit   BD Bioscience (Heidelberg, Germany) 
Bradford Protein Assay BioRad (Munich, Germany)       
CD4+ T Cell  Isolation Kit II Miltenyi Biotec (Bergisch Gladbach, Germany) 
CellTrace™ CFSE Cell Proliferation Kit Invitrogen (Darmstadt, Germany) 
mouse T cell activation and expansion Kit Miltenyi Biotec (Bergisch Gladbach, Germany) 
 
Standards 
 
2-log, 100bp and 1kb DNA ladder New England Biolabs (Frankfurt a.M., Germany)
Mark12 protein marker  Invitrogen (Darmstadt, Germany) 
Unstained Protein Molecular Weight Marker Fermentas GmbH (St.Leon-Rot, Germany) 
 
3.1.5. Bacterial Strains 
Strain Genotype  
E. coli TG1  K12 supE, hsdΔ5, thi, Δ(lac-proAB), F’[traD36, proAB+, 
lacIq, lacZΔM15] 
Promega (Mannheim, 
Germany) 
E.coli Rosetta 2DE3   F–, ompT, hsdSB(rB– mB–), gal dcm,  (DE3), 
pRARE  
Novagen (Darmstadt, 
Germany) 
E.coli Lemo21 (DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS/ 
pLemo(CamR) 
New England Biolabs 
(Frankfurt, Germany 
E.coli BL21(DE3) pLysS F– ompT hsdSB(rB–, mB–) gal dcm (DE3) pLysS 
(CamR) 
Invitrogen  (Darmstadt, 
Germany) 
E.coli SoluBl21 Optimized E. coli BL21 strain for expressing 
insoluble proteins in soluble form 
Genlantis, (SanDiego, 
USA) 
E.coli RosettaGami™ 
2(DE3) 
 
Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR 
araD139 ahpC galE galK rpsL (DE3) F′[lac+ lacIq 
pro] gor522::Tn10 trxB pRARE2 (CamR, StrR, TetR) 
Novagen (Darmstadt, 
Gerrmany) 
 
3.1.6. Media and antibiotics       
Antibiotics  Concentration 
Kanamycin 25 µg/mL 
Chloramphenicol 34 µg/mL 
Carbenicillin  60 µg/mL 
Ampicillin 100 µg/mL 
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Antibiotics  Concentration 
Streptomycin 50 µg/mL 
Tetracyclin 15 µg/mL 
   
Media Composition 
Luria Bertani (LB) 10 g/l Bactotryptone, 10 g/l NaCl, 5 mM NaOH, 5 g/l yeast extract 
Terrific Broth (TB) 
 
 
purchased from Roth GmbG & Co. KG (Karlsruhe, Germany),  
12 g/l BactoTryptone, 24 g/l Bacto-yeast-extract, 4 g/l glycerol, 17 mM, 
72 mM K2HPO4  
Autoinduction Medium (AIM) purchased from Novagen (Darmstadt, Germany) 
M9 Minimal Medium 
 
10 mL/L trace elements,  1mM MgSO4, 0.3 mM CaCl2, 100 ml/l M9 salt,  
2 g/l Glucose, 1.5 mg/L Thiamine, 1.5 mg/l  Biotin, 0,5 g/l NH4Cl  
M9 salt (10x) 64 g/l Na2PO4,  20 g/l KH2PO4,  5 g/l NaCL,  pH 7.2-7.3  
M9 trace elements 5 g/l EDTA , 500 mg/l FeSO4, 50 mg/l  ZnCl2, 10 mg/l CoSO4, 10 mg/l 
CuCl2, 10 mg/l H3BO3 , 1mg/l MnCl2 
     
3.1.7. Buffers 
2x SDS sample loading 
buffer 
100 mM Tris/HCl pH 6.8, 20 % Glycerol (v/v), 4 % SDS (w/v), 200 mmM 
DTT, 0.04  % (w/v) Bromphenol Blue 
Lysis buffer for test 
expression 
 
20 mM Hepes/NaOH pH 7.5, 150 mM NaCl, 1 µg/mL DNaseI, 0.1 mM 
Pefabloc, (2 mM DTT or 2 mM β-ME), 1 mg/mL Lysozyme I (Roth) or  
1 Volume of BugBuster Lysis Buffer (Merck) 
Lysis buffer for protein 
purification 
20 mM Hepes/NaOH pH 7.5, 150 mM NaCl, 1 µg/mL DNaseI, 0.1 mM 
Pefabloc, (2 mM DTT or 2 mM β-ME) 
Equilibration/ Wash buffer 
 
20 mM Hepes/NaOH pH 7.5, 150-300 mM NaCl, (2 mM DTT or 2 mM β-
ME) 
Elution buffer for His fusion 
proteins 
20 mM Hepes/NaOH pH 7.5, 150 mM NaCl, 150-300 mM Imidazol, (2 mM 
β-ME) 
Elution buffer for GST fusion 
proteins 
20 mM Hepes/NaOH pH 7.5, 150 mM NaCl, 20 mM glutathione , (2 mM 
DTT) 
Gel filtration buffer 20 mM Hepes/NaOH pH 7.5, 150 mM NaCl, 0,2 µM filtered, degassed 
SDS running buffer 25 mM Tris, 192 mM Glycine, 1 % (w/v) SDS 
Coomassie fixation solution 10 % (v/v) Acetic acid, 50 % (v/v) Ethanol 
Coomassie staining solution 10 % (v/v) Acetic acid, 0.025 % (w/v) Coomassie G250 
TAE buffer 40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
PBS Purchased from Invitrogen (Darmstadt, Germany) 
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FACS buffer PBS + 0.1 % (v/v) FCS 
Lysis buffer for genomic 
DNA isolation 
50 mM Tris, 100 mM EDTA, 0.5 % (w/v) SDS 
 
3.1.8. Plasmids 
Plasmid Properties  
pSKB2LNB2 
 
 
Prokaryotic expression vector for high-level expression of N-
terminally His6-tagged fusion protein, PreScission cleavage 
site, KanR   
Oliver Daumke, 
MDC 
 
pGex6p1 Prokaryotic expression vector for high-level expression of N-
terminally GST-tagged fusion proteins, PreScission cleavage 
site, AmpR   
GE Healthcare  
(Munich, Germany) 
 
3.1.9. Constructs and mutants 
The following is a list of all constructs generated for expression in E .coli.  
Construct Vector E.coli strain Remarks 
hsPRR (15-288) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3   
Rosetta 2DE3 
not soluble  
low amount soluble, precipitates 
hsPRR (15-300) 
 
 
 
pSKB2LNB2 
pGex6p1 
 
 
Rosetta 2DE3   
Rosetta 2DE3 
Lemo21 (DE3) 
SoluBl21 
not soluble 
low amount soluble, precipitates 
low expression, low amount soluble 
low expression, low amount soluble 
hsPRR (15-278) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (15-257) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (32-288) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (32-278) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (32-257) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (170-303) 
 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3 
Rosetta 2DE3 
soluble expressed, precipitates 
not soluble expressed 
hsPRR (62-303)  Rosetta 2DE3   not soluble expressed 
hsPRR (62-288) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (62-300) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (62-278) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (62-257) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (73-303) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (73-288) pGex6p1 Rosetta 2DE3   not soluble expressed 
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Construct Vector E.coli strain Remarks 
hsPRR (73-300) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (73-257) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (140-302) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (101-302) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (15-177) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (32- 177) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (62- 177) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (101-257) 
 
 
pGex6p1 
 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3   
 
BL21(DE3) pLysS 
Rosetta 2DE3 
soluble expressed, GST co-purified  
with PRR 
soluble expressed 
soluble expressed, highest yield 
hsPRR(101-257) S104G 
 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3   
Rosetta 2DE3 
soluble expressed, GST sticks to PRR 
soluble expressed 
hsPRR (132-257) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (140-302) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (132-302) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (101-302) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (106-257) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (106-278) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (106-288) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (106-302) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (101-278) pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (101-288) pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR(15-300)S104G pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR (32-278) S104G pGex6p1 Rosetta 2DE3   not soluble expressed 
hsPRR (62-288) S104G pGex6p1 Rosetta 2DE3 not soluble expressed 
hsPRR(101-302) S104G pGex6p1 Rosetta 2DE3  not soluble expressed 
hsPRR (120-257) 
 
pSKB2LNB2 
 
pGex6p1 
Rosetta 2DE3 
BL21(DE3) pLysS 
Rosetta 2DE3 
BL21(DE3) pLysS 
not soluble expressed 
not soluble expressed 
not soluble expressed 
very low amount soluble 
hsPRR (141-257) 
 
pSKB2LNB2 
 
pGex6p1 
Rosetta 2DE3 
BL21(DE3) pLysS 
Rosetta 2DE3 
BL21(DE3) pLysS 
no over expression 
no over expression 
no over expression 
no over expression 
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Construct Vector E.coli strain Remarks 
hsPRR (166-257) 
 
pSKB2LNB2 
 
pGex6p1 
Rosetta 2DE3 
BL21(DE3) pLysS 
Rosetta 2DE3 
BL21(DE3) pLysS 
soluble expressed, highest yield 
soluble expressed 
soluble expressed  
soluble expressed 
hsPRR (166-269) pSKB2LNB2 Rosetta 2DE3 soluble expressed, dirty 
hsPRR (174-257) pSKB2LNB2 Rosetta 2DE3 soluble expressed, dirty 
hsPRR(170-302) SER 
KQAK284-287 AAAA 
pSKB2LNB2 
 
Rosetta 2DE3 
 
not soluble expressed 
hsPRR(101-257) SER 
EE120/121 AA 
pGex6p1 Rosetta 2DE3 
 
low overexpression, 
not soluble expressed 
hsPRR(101-257) SER 
EE 131/132 AA 
pGex6p1 Rosetta 2DE3 
 
low overexpression, 
not soluble expressed 
hsPRR(15-300)  SER 
KE 55AA 
pSKB2LNB2 Rosetta 2DE3 not soluble expressed 
hsPRR(15-300)  SER 
EE120/121 AA 
pSKB2LNB2 
 
Rosetta 2DE3 
 
not soluble expressed 
hsPRR(15-300)  SER 
EE 131/132 AA 
pSKB2LNB2 
 
Rosetta 2DE3 
 
not soluble expressed 
hsPRR(15-300)  SER 
KQAK284-287 AAAA 
pSKB2LNB2 
 
Rosetta 2DE3 
 
not soluble expressed 
hsPRR(166-257) 
201 AAAAAAA 207 
pSKB2LNB2 
 
Rosetta 2DE3 
 
soluble expressed, high yield 
higher expression w/o mutation 
mm PRR (16-288) pSKB2LNB2 
pGex6p1 
Rosetta 2DE3   
Rosetta 2DE3 
not soluble expressed 
not soluble expressed 
mm PRR (16-300) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
not soluble expressed 
not soluble expressed 
mm PRR (101-257) pSKB2LNB2 Rosetta 2DE3 not soluble expressed 
mm PRR (166-257) pSKB2LNB2 Rosetta 2DE3 low amount of soluble protein 
xl PRR (98-254) pSKB2LNB2 Rosetta 2DE3   no expression 
xl PRR (163-254) pSKB2LNB2 Rosetta 2DE3 low amount of soluble protein 
xl PRR (14-286) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
low expression, not soluble 
no expression 
xl PRR (14-298) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
no expression 
no expression 
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Construct Vector E.coli strain Remarks 
dr PRR (99-255) pSKB2LNB2 Rosetta 2DE3 low amount of soluble protein 
dr PRR (164-255) pSKB2LNB2 Rosetta 2DE3 soluble expressed 
dr PRR (15-287) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3   
Rosetta 2DE3 
not soluble expressed 
not soluble expressed 
dr PRR (15-299) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
not soluble expressed 
not soluble expressed 
hs Renin (23-407) 
 
 
 
pSKB2LNB2 
 
pGex6p1 
 
Rosetta 2DE3 
RosettaGami 
Rosetta 2DE3 
RosettaGami 
low expression, not soluble 
no expression 
not soluble expressed 
no expression 
hs Prorenin (66-407) 
 
 
 
pSKB2LNB2 
 
pGex6p1 
 
Rosetta 2DE3   
RosettaGami 
Rosetta 2DE3 
RosettaGami 
low expression, not soluble 
no expression 
not soluble expressed 
no expression 
mm Renin2 (86-425) pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
no expression 
not soluble expressed 
mm Prorenin2 (48-425) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
no expression 
not soluble expressed 
rn Renin (64-403) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3 
Rosetta 2DE3 
low expression, not soluble 
not soluble expressed 
rn Prorenin (26-403) 
 
pSKB2LNB2 
pGex6p1 
Rosetta 2DE3   
Rosetta 2DE3 
low expression, not soluble 
not soluble expressed  
coexpression      
hs Renin (23-407) +  
hs PRR (15-300) 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3 
 
no expression 
 
hs Renin (23-407) +  
hs PRR (15-288) 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3 
 
low expression PRR, not soluble,  
no expression Renin 
hs Prorenin (66-407) +  
hs PRR (15-300) 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3 
 
low expression PRR, not soluble,  
no expression Renin 
hs Prorenin (66-407) +  
hs PRR (15-288) 
pGex6p1 
pSKB2LNB2 
Rosetta 2DE3 
 
low expression PRR, not soluble,  
no expression Renin 
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3.1.10. Antibodies and staining reagents for flow cytometry 
Specificity Conjugate Manufacturer 
mCD3 APC cy7 BD Bioscience (Heidelberg, Germany) 
mCD4 
 
Cy5 
biotinylated 
BD Bioscience (Heidelberg, Germany) 
DRFZ (Berlin, Germany) 
mCD8a 
 
PE 
biotinylated 
BD Bioscience (Heidelberg, Germany) 
DRFZ (Berlin, Germany) 
mCD25 PE BD Bioscience (Heidelberg, Germany) 
mCD44 Cy5 BD Bioscience (Heidelberg, Germany) 
mCD45 FITC BD Bioscience (Heidelberg, Germany) 
mCD45R biotinylated BD Bioscience (Heidelberg, Germany) 
Streptavidin PerCP BD Bioscience (Heidelberg, Germany) 
Annexin V Cy5 BD Bioscience (Heidelberg, Germany) 
 
3.1.11. Recombinant proteins 
Recombinant human Renin, 6xHisRenin and 6xHisProrenin were provided by Actelion 
Pharmaceuticals Ltd. (Allschwil, Switzerland). 
 
3.1.12. Animals  
The animals used for this work were bred under pathogen free conditions in the animal care 
unit of the MDC.  
Strain Genotype Obtained from 
C57/BL6  floxed PRR  Genevieve Nguyen, College de France,  Paris   
C57/BL6 LcK Cre Achim Leutz, MDC, Berlin 
 
3.1.13. Primers and oligonucleotides  
Primers and oligonucleotides were synthesised by Biotez (Berlin, Germany) 
Genotyping primer 
Name Sequence (5´-3´) 
PRR 1 fw(Lf) 5´ AGC ACT CTC TTC CAG GTA TGT TGT G 3´ 
PRR 2 fw (Ef) 5´CTG GAT CCC GGA GCA TGG GTA AAG G 3´
PRR rev (Er) 5´ GCT GTC CAAAGA AAC CAG AGC C 3´ 
Lck cre fw 5´GCT GCC ACG GCC AAG TG 3´ 
Lck cre rev 5´TCG GCA TCT TCC AGC AG 3´ 
 
 38
3. Materials and methods
 
The primer and oligonucleotides for real-time PCR were designed using Primer Express®ABI 
PRISM software to be species specific (except for the eukaryotic18s primer and probe) and 
exon overlapping.  
Name Sequence 5´-3´ 
r18s fw 5´ ACATCCAAGGAAGGCAGCAG 3´ 
r18s rev 5´ TTTTCGTCACTACCTCCCCG 3´ 
r18s probe 5´ FAM-CGCGCAAATTACCCACTCCCGAC-TAMRA 3´ 
mmPRR fw 5' CCAGTTTGTTGTCTCGTCATAAGC 3' 
mmPRR rev 5' ACCTGCCAGCTCCAATGAAT 3' 
mmPRR probe 5' FAM-TCTAGCCAAGGACCATTCACCCGACTT-TAMRA 3' 
 
3.1.14. Hardware  
 
 
NanoDrop®ND1000 PEQLAB Biotechnologie GMBH (Erlangen, Germany)  
7500 Fast Real-Time PCR System Applied Biosystems (Carlsbad, USA) 
FACSCanto BD Bioscience (Heidelberg, Germany) 
Viscotek 270 Dual detector Malvern Instruments Ltd. (Worcestershire, UK) 
Microfluidiser  Microfluidics (Newton, USA) 
XL-A type analytical ultracentrifuge Beckman Coulter (Palo Alto, USA) 
Jasco L-720 spectropolarimeter Jasco Corp. (Hachioji, Japan) 
Hydra plus one crystallization robot   Thermo Scientific (Karlsruhe, Germany) 
3.1.15. Software 
7500 Fast System Software Applied Biosystems (Carlsbad, USA) 
Primer Express®ABI PRISM Applied Biosystems (Carlsbad, USA) 
Netprimer PREMIER Biosoft International (Palo Alto,USA)     
OmniSec Malvern Instruments Ltd. (Worcestershire, UK) 
Bioedit IbisBiosciences  (Carlsbad, USA) 
GraphPadPrism  GraphPad Software, Inc. (San Diego, USA) 
FlowJo  Tree Star, Inc. (Ashland, USA) 
FACS Diva BD Bioscience (Heidelberg, Germany) 
Sedfit Peter Schuck 135 
Sedphat  Peter Schuck 135 
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3.1.16. Statistics 
All experiments were analysed for at least n=5 for the WT groups and n=3 (spleen) or n=4 
(thymus) for the KO group. All statistical tests were performed using GraphPadPrism. The 
data were analyzed for Gaussian distribution by using the Kolmogorov-Smirnov-test. Because 
of the low amount of animals per KO group, a Gaussian distribution could not be confirmed 
for all of the KO groups. Therefore, the Mann-Whitney-test was used to test for significance 
between the WT and KO group. For the analysis of the different cell subsets in the thymus, a 
one-way-ANOVA with Tukey post-hoc test was used. Results were considered significant if 
the p-value was (p) < 0.05.       
 
3.2. Molecular biology methods 
3.2.1. Construct design 
The constructs were designed based on sequence alignments program (ClustalW algorithm 136) 
and a secondary structure predictions (Jpred3 137). The sequence alignment is in the appendix.   
 
3.2.2. Polymerase chain reaction (PCR) 
Amplification of DNA fragments was performed using Pfu DNA polymerase (Roboklon) 
following standard protocols described in Sambrook et al. 138. 
 
3.2.3. Restriction digest 
Plasmid DNA and PCR fragments were digested with restriction enzymes obtained from New 
England Biolabs, according to the manufacturer’s protocol. 
 
3.2.4. Agarose gel electrophoresis 
Agarose gel electrophoresis was performed according to standard procedures 138. 
 
3.2.5. DNA gel extraction  
PCR fragments or digested Plasmid DNA were first run on an agarose gel. Fragments of the 
expected size were cut from the gel and subsequently purified with the QIAquick Gel 
Extraction kit (Qiagen), according to the manufacturer’s protocol. The quality and quantity of 
purified DNA was determined with a Nanodrop spectrophotometer (Peqlab) at a wavelength 
of 260 nm. 
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3.2.6. Ligation 
Ligation was performed overnight at 4°C using 12 ng of digested vector and a 12 molar 
excess of the purified insert after addition of T4 DNA ligase (New England Biolabs). 
 
3.2.7. Transformation 
Ligation products were cloned into the TG1 K12 E.coli strain according to the heat shock 
method of Sambrook et al. 138. For protein expression, purified and sequence verified 
plasmids were transformed into Rosetta 2DE3, BL21 (DE3) pLysS, Lemo21 (DE3) or 
SoluBl21 E.coli strains using standard protocols. 
 
3.2.8. Preparation of heat competent E.coli cells 
Competent cells were prepared according to the protocol of Chung et.al. 139. Bacteria were 
grown at 37°C in 200ml of LB medium from a 2 ml overnight pre-culture, until an OD600nm of 
0.4-0.5 was reached. The cells were incubated for 20 min on ice, then centrifuged for 5 min at 
1,200 g and 4°C, and then the pellet was resuspended in 20 ml of ice-cold sterile TSS buffer 
(85% LB medium without NaOH, 10% PEG8000 or 3350, 5% DMSO, 50 mM MgCl2, pH 
6.5). E.coli cells were then aliquoted, flash frozen and stored at -80°C. 
 
3.2.9. Plasmid purification 
Plasmids were purified from 5mL overnight cultures with the Plasmid Purification Mini Kit 
(Qiagen), according to the manufacturer’s protocol. Quality and quantity of purified DNA 
was determined with a Nanodrop spectrophotometer (Peqlab) at a wavelength of 260 nm. 
 
3.2.10. Site directed mutagenesis 
Mutagenesis of plasmids was performed using a site directed mutagenesis PCR kit, using 
KOD DNA polymerase (Novagen), followed by digest with Dpn1 (New England Biolabs) and 
transformation into the TG1 K12 E.coli strain.  All steps were performed according to the 
Quick Change protocol (Stratagene). 
   
3.2.11. Bacterial storage 
E.coli transformed with the desired plasmid were grown overnight and glycerol stocks were 
prepared according to standard procedures and then stored at -80 °C. 
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3.2.12. RNA isolation 
Cells or tissues were homogenized in a Precelly24 homogenater (Peqlab) by adding Qiazol 
lysis reagent (Qiagen) and 2.8 mm ceramic beads (Peqlab).  After centrifugation the aqueous 
RNA phase was applied onto spin columns of RNAeasy Kit (Qiagen). An on-column DNAse 
digest (Qiagen) was performed after first washing the bound RNA once. All other steps were 
performed according to the RNAeasy manual. The quality and quantity of the RNA was 
determined with a Nanodrop spectrophotometer at a wavelength of 260 nm. 
 
3.2.13. cDNA transcription 
2 µg of purified RNA was transcribed to cDNA using the Superscript III cDNA Synthesis Kit 
(Invitrogen) according to the manufacturer’s protocol. 
 
3.2.14. Real-Time PCR 
Real-Time PCR was performed on a 7500 Fast Real-Time PCR System using TaqMan® Fast 
Universal PCR Master Mix (both Applied Biosystems) according to the manufacturer’s 
protocol. Per sample, 0.2 ng cDNA was used and all samples were measured in triplicate.  
Data was evaluated with the 7500 Fast System Software (Applied Biosystems) and the 
samples were normalized against a housekeeper gene, 18s. 
 
3.2.15. Mouse genotyping 
Isolation of genomic DNA from tail cuts was performed with the direct PCR Tail lysis reagent 
(Peqlab), following the manufacturer’s protocol .The genomic DNA was amplified with the 
REDTaq® ReadyMix™ PCR Reaction Kit (Sigma Aldrich) according to the manual. 
Fragments were analyzed on an agarose gel. 
 
3.2.16. Isolation of genomic DNA 
DNA was isolated from different organs and cells with Phase Lock Gel™ tubes (5Prime, 
Hamburg, Germany) and a phenol/chloroform extraction of nucleic acids was performed 
according to the manufacturer’s protocol. 
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3.3. Biochemical methods 
3.3.1. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed for the separation of proteins of different molecular weight based 
on the standard protocol described by Laemmli et al. 140. Alternatively, purchased gradient 
gels NuPAGE® Novex 4-12 % Bis-Tris (Invitrogen) were used according to the 
manufacturer’s protocol. Samples were mixed with a 2x SDS sample loading buffer (see 
3.1.7.), boiled for 5 min at 95 °C and then loaded onto the gel. 
 
3.3.2. Coomassie staining  
SDS-polyacrylamide gels were first fixed in coomassie fixation solution (see 3.1.7.) for at 
least 15 minutes, and then stained in coomassie staining solution for a minimum of 15 min. 
Gels were then washed with water until the background went clear.  
 
3.3.3. Determination of protein concentration 
Protein concentration was determined using a Nanodrop spectrophotometer (Peqlab) at a 
wavelength of 280 nm. The concentration was calculated according to the Beer-Lambert 
equation using the respective molecular weight and the extinction coefficient 141. 
Additionally, the Bradford Protein Assay (Roth) was used according to the manufacturer’s 
protocol 142. 
 
3.3.4. Small-scale over-expression and solubility test 
For small-scale over-expression and solubility test, respective plasmids were transformed into 
the required E.coli expression strains (see 3.1.5. and 3.2.7.). These test inductions were 
performed with an auto induction media (AIM) (Novagen). AIM enables the growth of IPTG-
inducible expression strains and induces target protein expression automatically. This is 
achieved as follows: The media contains a limited concentration of glucose. By depletion of 
glucose during mid to late log growth phase, lactose is taken up and converted into 
allolactose. Allolactose induces expression of the T7 RNA polymerase and its target proteins 
143. Fresh overnight colonies were used to inoculate 1 ml of AIM in 24-well plates. The 24-
well plates were then incubated for 8 hours at 37°C and 900 rpm on a thermomixer 
(Eppendorf). Afterwards, the temperature was lowered to 20 °C and cultures were incubated 
overnight.  After approximately 18-20 hours, bacterial cells were harvested by centrifugation 
for 15 min at 4 °C and 5000 rpm. To aid with lysis, the cell pellet was first frozen at -80 °C 
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for at least 30 min or quickly frozen in liquid nitrogen. The pellet was then resuspended in 
300 µL of lysis buffer (see 3.1.7.) and incubated for 30 min at 15 °C and 350 rpm on a 
thermomixer. An aliquot was taken from the lysate for analysis of the induced sample by 
SDS-PAGE. The lysate was then centrifuged for 20 min at 4 °C and 13000 rpm. A sample 
from the supernatant was taken for analysis of the soluble proteins by SDS-PAGE. All 
samples for SDS-PAGE were then mixed with 2x SDS sample loading buffer and then loaded 
on to the gel. After Coomassie staining, the gel was scrutinized for the presence of soluble 
recombinant protein. Positive clones with relatively high soluble expression were then used 
for large scale expression and purification (see 3.3.5. and 3.3.6.). In some cases, small-scale 
affinity purification was performed. Here, the supernatant was incubated with 50µl of Talon 
resin or GSH sepharose. The beads were washed once, and then the protein was eluted with 
the respective buffer (see 3.1.7.) 
 
3.3.5. Large-scale over-expression 
A fresh overnight culture in LB media was used to inoculate (1:100) 5 to 10 L of TB media 
including antibiotics. Cultures were incubated at 37 °C under constant shaking until an 
OD600nm of 0.4-0.5 was reached. Cells were then cooled to 18 °C and protein expression was 
induced by the addition of Isopropyl-β-D-thiogalactopyranosid (IPTG; 40µM). Proteins 
expression was induced overnight. Bacteria were harvested by centrifugation for 15 min at 
4°C and 5000 rpm. Pellets were then resuspended in lysis buffer (see 3.1.7.) and used directly 
for large scale purification or stored at -30°C. For NMR experiments and over-expression in 
SoluBl21, cells were grown in minimal media under the same conditions. 
 
3.3.6. Large-scale purification 
3.3.6.1.Cell lysis and sample preparation 
Frozen cells were first thawed in cold water. DNase I was then added and the cells were lysed 
with a microfluidiser (Microfluidics, Newton, USA). The lysate was centrifuged for 30-45 
min at 35000rpm and 4°C. The supernatant was then passed through a 0.45 µM or 0.2 µM 
filter to prevent obstruction of the purification columns. Aliquots of the induced lysate and 
lysate supernatant fractions were removed for subsequent analysis on SDS-PAGE.   
3.3.6.2.Affinity chromatography 
The supernatant was applied onto an equilibrated affinity chromatography column with a flow 
rate of 1-2 ml/min. Depending on the expression vector and the corresponding tag, these 
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columns were either a 5-10ml Talon cobalt affinity column (Clontech, Saint-Germain-en-
Laye, France) or a 10-20 ml reduced glutathione (GSH)-Sepharose column (GE Healthcare). 
The columns were then washed with at least 15 column volumes of washing buffer (see 
3.1.7.). The GSH column was furthermore treated with a washing buffer with high salt 
(300mM) conditions. Bound protein was then eluted in 5 ml fractions with the corresponding 
elution buffer (see 3.1.7.). The GSH elution buffer was additionally incubated for 5 to 10 min 
with the column material before elution. The eluted fractions were analyzed with Bradford 
Reagent (Roth) for protein content. Aliquots for flow through, wash and elution fractions 
were taken for analysis on SDS-PAGE.  
3.3.6.3.Tag cleavage 
The protein concentration of the elution fractions were determined and analyzed for purity on 
SDS-PAGE. The fractions with the highest yield and purity were then pooled. Tag cleavage 
was performed overnight at 4°C with approximately 10µg of Prescission Protease per 1mg of 
eluted protein. As the protease is active under reducing conditions, if the elution buffer did not 
contain a reducing reagent, 2 mM DTT or 2mM β-ME were added. All samples were first 
dialysed overnight at 4°C against the gel filtration buffer (see 3.1.7.) to dilute the imidazol or 
gluthathione concentration. In some cases, the GST-tagged proteins were directly cleaved on 
the column material. Here, the GST remains bound to the column whilst the un-tagged protein 
is washed out after cleavage. Analysis of cleavage success was analysed by SDS-PAGE. 
3.3.6.4.Removal of Prescission Protease 
All samples were passed over a 1ml GSH column to remove the GST tagged Prescission 
Protease and the cleaved GST tag (for GST-tagged proteins). All His-tagged proteins were 
additionally passed over a Talon column again to remove any contaminating proteins.  
3.3.6.5.Size-exclusion chromatography 
The final purification step was size exclusion chromatography. The protein was first 
concentrated with amicon filters (Millipore) and centrifuged for 10 min at 4°C and 13000 rpm 
to remove precipitate. Depending on the molecular weight and the amount of protein, the 
concentrated sample was then run on either a Superdex 200 or Superdex 75 in 16/60 or 26/60 
gel filtration columns (GE Healthcare).  The elution fractions were analyzed on SDS-PAGE 
and the fractions corresponding to the respective protein were pooled. 
 
 45
3. Materials and methods
 
3.3.7. Protein storage 
Purified protein samples were concentrated with amicon filters (Millipore) and the 
concentration was determined (3.3.3.). Small aliquots were flash frozen in gel filtration buffer 
(see 3.1.7.) liquid nitrogen and stored at -80°C. 
 
3.3.8. GST pull-down assay 
For GST pull-down assays, the GST tag was not cleaved from the recombinant PRR proteins. 
Recombinant human renin or prorenin was then incubated with equimolar amounts of GST-
tagged PRR proteins.  The mixture was incubated overnight at 4°C with GSH Sepharose. The 
next day, unbound proteins were washed from the beads and the bound protein was eluted 
with elution buffer (3.1.7.).  Aliquots from the unbound and bound fraction were then 
analyzed by SDS-PAGE. 
 
3.3.9. Limited proteolyis assay 
During this assay, protein samples are incubated with low concentrations of proteases. 
Flexible regions within the protein structure are preferentially cut by the proteases, thereby 
the stable structural region of the protein can be identified. This then allows the design of 
more stable proteins, which would be more likely to crystallise. The proteins were incubated 
with the following proteases: Trypsin, Thermolysin, Subtilisin and Chymotrypsin at two 
dilutions (1:100, 1:1000). The samples were incubated for 20 min either at 4°C or 37°C. 
Proteolysis was stopped by the addition of 2x SDS loading buffer, and the samples were then 
analyzed by SDS-PAGE.  The protein fragments were cut from the SDS-PAGE and digested 
with trypsin for identification by mass spectrometry. Mass spectroscopy experiments and data 
analysis were performed by Gunnar Dittmar (MDC).  
 
3.3.10. Chemical cross-linking  
Chemical cross-linking was performed to examine if the proteins formed dimers or higher 
oligomers.  Bis[sulfosuccinimidyl] suberate (BS3)  (Thermo Scientific) contains an amine-
reactive N-hydroxysulfosuccinimide (NHS) ester that reacts with primary amines at pH 7-9 to 
form stable amide bonds. All cross linking experiments were performed according to the 
manufacturer’s protocol. After cross-linking samples were analyzed on SDS-PAGE. 
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3.4. Biophysical methods 
3.4.1. Right-angle light-scattering (RALS) 
Right-angle light-scattering measures the intensity of the scattered light to determine the 
average molecular weight (Mw) of a protein. With this method it is therefore possible to 
obtain information about the monomeric or oligomeric state of a protein 144.  A refractive 
index and UV detector were coupled to a RALS system (Viscotek 270 Dual detector, Malvern 
Instruments). All detectors were connected in line with an analytical (Superdex 200 or 
Superdex 75, 10/300) gel filtration column (GE Healthcare) at 4°C. The whole system was 
equilibrated for at least 3 column volumes at a flow rate of 0.5ml/min with gel filtration buffer 
(see 3.1.7.). The protein samples were first filtered through a 0.2µm filter and then loaded 
onto the column. For each sample, 100 μl of a 0.5 -10 mg/ml solution was used. Data was 
analyzed with the OmniSec software (Malvern).  
 
3.4.2. Circular dichroism (CD) 
Circular dichroism (CD) spectroscopy measures the difference in the absorbance of right- and 
left-circularly polarized light.  CD is monitored between 260 and 180 nm for analysis of 
protein secondary structure. Alpha-helix, beta-sheet, and random coil structures each give rise 
to a characteristic CD spectrum. Alpha-helical proteins typically have peaks of negative 
ellipticity at 222nm and 208 nm, whilst predominantly beta-sheet proteins have a single peak 
of negative ellipticity at 218nm 145-149. 
CD spectra were recorded on Jasco L-720 spectropolarimeter (Jasco Corp.) or on a Chirascan 
Circular Dichroism Spectrometer (Applied Photophysics). The samples were routinely 
measured at 20ºC (unless indicated) with a resolution of 1nm over the wavelength range of 
180-260nm. Samples in NaCl buffer were dialysed into buffer containing NaFl, because Cl 
interferes with the measurement. Samples were diluted to 0.2mg/ml and transferred to 1mm 
cuvettes. To estimate the percentage of alpha-helical, beta-sheet or random-coil secondary 
structure, the data was analyzed with a protocol established by Sandro Keller (University 
Kaiserslautern). The specific melting temperature (Tm) of each protein was determined by 
heating the samples 1°C per minute from 4°C to 94°C. A CD signal at 222nm was obtained at 
every temperature interval. A full CD spectrum (180-260nm) was also measured before and 
after the Tm analysis, to monitor if the proteins had precipitated during the experiment.  
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3.4.3. Analytical Ultracentrifugation (AUC) 
All experiments were performed in a XL-A type analytical ultracentrifuge (Beckman) 
equipped with UV absorbance optics. 
3.4.3.1.Sedimentation velocity  
Sedimentation velocity is an analytical ultracentrifugation (AUC) method that measures the 
rate at which molecules move in response to centrifugal force. The time course of 
sedimentation provides information about the molecular mass and the shape of molecules that 
is described by the sedimentation coefficient, Svedberg (S) 135, 150, 151.  
Sedimentation velocity experiments were carried out in two-channel cells with a total volume 
of 360µL for each sample. The concentration of the protein samples were chosen to have an 
optimal absorbance at 280nm between OD 0.1-1. Samples were centrifuged at 40000 rpm and 
20°C. Sedimentation velocity profiles were analyzed with the program SEDFIT 135, using a 
model for continuous c(s) distribution. 
3.4.3.2.Sedimentation equilibrium  
Sedimentation equilibrium is the analysis of the steady-state dispersion of a protein in a 
centrifugal cell, achieved when the rate of sedimentation of the protein is equal to the 
opposing rate of diffusion. Thereby, sedimentation equilibrium is insensitive to the shape of 
the macromolecule and directly reports the molar mass. 
Sedimentation equilibrium experiments were carried out using six-channel cells with a 12 mm 
optical path length and a total volume for each sample of 70 μl. Molecular mass studies of 
hsPRR 166-257 were performed at several different protein concentrations (0.25, 0.5, 0.75, 1, 
1.5, 2 mg/mL). The samples were centrifuged at 20000, 25000 and 35000 rpm until 
equilibrium was reached (overnight). Radial scans with a step size of 0.001 cm was recorded 
at equilibrium and the data was analyzed with the programs SEDFIT and SEDPHAT 135 using  
the species analysis model. 
 
3.4.4. Protein crystallization trials 
Proteins can form crystals under certain conditions. Nucleation is the starting point for 
crystallization and happens at high levels of supersaturation. A crystal is a regular and 
periodic arrangement of proteins in a three dimensional manner and is the basis for protein x-
ray crystallography.  Crystallization trials were performed with the hsPRR(170-303), 
hsPRR(101-257), hsPRR(166-257), hsPRR(166-257) 201AAAAAA207 and drPRR(164-255). 
Commercially available crystal screens such as pHClear, pHClear II, Classics, Classics II, 
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ClassicsLite, JCSG, JBS, JBS/JCSG, PEGs and PEGs II, from Qiagen, Hampton Research 
and Jena Bioscience were used for initial screens. Protein concentrations ranged from 5- 
40mg/mL. Crystallisation drops for the various screens were pipetted with the Hydra plus one 
robot (Thermo Scientific), using the sitting-drop vapour-diffusion method. In each trial, 300 
nl of protein and 300 nl crystallization buffer were spotted onto the crystal plate (Crystal 
Quick 96 well plates, Greiner BioOne) with an additional 75 µl of reservoir solution. For the 
hsPRR 166-257 and the hsPRR 101-257 additional manual screens using the hanging-drop 
vapour-diffusion method were made. In these cases, 24-well plates (SuperClear Pregreased 
24-well plates, Crystalgen) were used for the screens with a reservoir volume of 750µL. 1µl 
of protein and 1µL of crystallization buffer were mixed on a coverslip, which was then 
suspended over the resorvoir. Different precipitants (PEGs, isopropanol, ammonium sulfate, 
MPD), buffer (pH ranging from 4.5-9) and salt (48 different ions) conditions were 
successively tested. The best conditions were considered for the design and preparation of the 
following screen. In both the screens and manual trials, plates were stored at 4°C or 20°C. 
 
3.4.5. Nuclear magnetic resonance (NMR) spectroscopy 
Solution-state nuclear magnetic resonance (NMR) spectroscopy is a method which is used to 
obtain structural and functional information about molecules; ranging from small chemical 
compounds up to proteins with a maximal molecular weight of ~35 kDa. Only isotopes with 
an odd number of neutrons and protons have a spin. The spin is required to be observable in 
NMR. Therefore it is necessary to isotopically label the protein with 13C and 15N. The 
naturally occurring isotope 12C is not NMR active. In 1H–15N heteronuclear single-quantum 
correlation spectroscopy (HSQC) the frequencies for the 1H–15N are correlated. This method 
gives one peak per pair of bonded nuclei. Thus, for every amino acid, one signal for the 
backbone amide group (except proline) should be detected.  
For the HSQC experiment hsPRR (166-257) was single labelled with 15N isotopes (see  
3.3.5.). The sample was then measured at a concentration of 1 mM in 100 mM NaCl and 50 
mM phosphate buffer pH 7.5 at 20 °C (AV750, spectrophotometer, Bruker). All NMR 
experiments were performed in collaboration with Peter Schmieder (FMP, Berlin). 
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3.5. Cell biological methods 
3.5.1. Isolation of lymphocytes from blood 
Blood was isolated from 6-8 week old mice using heparinised syringes. 1 volume of blood 
was incubated with 9 volumes of erythrocyte lysis buffer (155mM NH4Cl, 10mM NaHCO3, 
1mM EDTA) for 5 min at 37°C. The reaction was stopped by the addition of 1 volume of ice 
cold PBS + 0.1% FCS and the lymphocytes were then washed twice with PBS + 0.1% FCS. 
Purified cells were counted with the Countess Automated Cell Counter (Invitrogen) and 
analyzed for cell vitality with trypan blue staining. 
 
3.5.2. Isolation of single cell suspensions from spleen and thymus  
Splenocytes were isolated from 6-8 week old mice and thymocytes were isolated from 4-6 
week old mice. Tissues were kept in ice cold PBS + 0.1% FCS and all steps were performed 
on ice. Spleen and thymus samples were first passed through a 70µM cell strainer (BD 
Bioscience) and were then washed twice with PBS + 0.1% FCS. Purified cells were counted 
and analyzed for cell vitality.  
 
3.5.3. CD4+ cell isolation 
CD4+ cells were isolated from spleen and lymph node cell suspensions of 6-8 week old mice. 
CD4+ cells were purified using the CD4+ T Cell Isolation Kit II (Milteny) according to 
manufacturer’s recommendation. Purity of the cell isolation was confirmed by staining the 
cells with a CD4+ antibody and analyzing by flow cytometry (see 3.5.5). 
 
3.5.4. Isolation of CD4-/CD8- double negative lymphocytes 
CD4-/CD8- double negative lymphocytes were isolated from the thymus using magnetic cell 
sorting (MACS). First, thymocytes were separated (see 3.5.2.) and erythrocytes were lysed 
(see 3.5.1.). Then, CD4+, CD8+ single or double positive cells were stained and removed by 
MACS, thereby enriching the CD4-/CD8- double negative lymphocytes that pass through the 
column. The cells were pre-incubated for 10 min with a blocking reagent (Fcγ, RZPD) and 
then stained with biotinylated mCD4+ and biotinylated mCD8+ antibodies (1:100) for 10 min 
at 4°C.  After washing, the thymocytes were then incubated with anti Biotin Microbeads 
(Milteny) for 15 min and isolated with a QuadroMACS separator and LS columns (Milteny), 
according to the manufacturer’s protocol. 
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3.5.5. Flow cytometry 
Flow cytometry is a method where the size and phenotype of single cells are characterized as 
they pass through a laser beam. The scattered light provides information simultaneously about 
size and granularity of cells, whilst the fluorescence emission gives information about the 
cellular expression of membrane bound or intracellular proteins that were first stained with 
fluorescently labelled antibodies. All experiments were performed on FACSCanto (BD 
Bioscience) and data was analyzed using the programs FACSDiva and FlowJo software.  
For extracellular staining, 1x106 cells in 100 µL of FACS buffer were incubated with the 
desired fluorescently labelled antibodies for 15 min at 4°C in the dark. If necessary, the cells 
were incubated with a second antibody after a single washing step. For intracellular staining, 
the cells were first permeabilized using the CytoFix/CytoPerm Solution Kit (BD Bioscience), 
according to the manufacturer’s protocol. Antibody incubation of permeabilized cells was 
performed as for extracellular staining protocol. 
 
3.5.6. Apoptosis staining 
When cells undergo apoptosis, phosphatidylserine translocates from the intracellular to the 
extracellular side of the cell membrane.  Annexin V binds to phosphatidylserine and is 
detectable on the cell surface. Purified and prestained (CD4, CD8) cells were stained with 
Cy5 labelled Annexin V (BD Bioscience) according to the manufacturer’s protocol and 
analyzed by flow cytometry (see. 3.5.5) 
 
4. Results
 
4. Results 
4.1. Expression and design of recombinant PRR proteins 
4.1.1. Protein test-expression and solubility  
One aim of this thesis was to structurally and biochemically characterize PRR. As it has been 
previously found that the full-length PRR (containing the transmembrane region) could not be 
purified (personal communication, G. Nguyen, College de France), the focus was set on the 
expression on the soluble, extracellular domain (Figure 8). The first step for the structural and 
biochemical characterisation of a protein is the production of sufficient amounts of 
recombinant protein of high purity. An E.coli expression system was used, because high 
amounts of protein can be purified and the system is time and cost efficient. E.coli was also 
suitable because no post-translational modifications such as glycosylation are known for PRR. 
These are limitations for bacterial expression systems.  
The constructs were designed based on sequence alignments (ClustalW algorithm 136) and  
secondary structure predictions (Jpred3 137) (see Appendix).   
 
full-length PRR 
soluble 
 
Figure 8. Schematic representation of human PRR and its domains.  
PRR consists of a short intracellular (ID), a transmembrane (TM) and an extracellular (ED) domain. Also shown 
is the PRR signalpeptide (SP) and the furin cleavage site (RKTR) in the extracellular domain. The soluble 
human PRR proteins purified in this project are depicted below. 
 
To find a soluble construct, test-expressions for all constructs were carried out, as described in 
section 3.3.4. Figure 9 shows an example of a typical test-expression. The protein was over-
expressed and, after cell lysis, the insoluble (in) and soluble fractions (SN) analysed by SDS-
PAGE. In this example, the human (hs) PRR (166-257) was over expressed and tested for 
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solubility. Clones in lane a and b did not express hsPRR (166-257), but in lane c and d the 
protein is highly expressed and a large proportion was found in the soluble fraction. 
hsPRR (166-257)
Lysozym
in SN
116
25
35
45
66
14
18
a b cM ddb ca
kDa  
 
Figure 9. Test-expression of the hsPRR (166-257) constructs.  
Different expression clones were tested for soluble protein (a-d). Sample a and b show no overexpression while c 
and d are overexpressing the protein, which is also soluble.  In this example the induced and soluble fractions of 
hsPRR(166-257) are shown. The red box indicates the over expressed (in) and the soluble fraction (SN). 
Lysozyme was added to the lysis buffer. 
  
During these expression and solubility tests more then 50 PRR constructs were screened from 
various species (Homo sapiens, Mus musculus, Danio rerio, Xenopus laevis), in two different 
expression vectors, with either a 6xHis or GST-tag. In addition, to achieve better amounts of 
soluble protein surface entropy reduction mutations using the SERp server were introduced 
152. This server recognizes clusters of flexible, solvent-exposed residues and replaces them 
with residues with lower conformational entropy to enhance a proteins ability to be 
crystallized. Furthermore, I tested different E.coli expression strains to test if this would 
enhance solubility. As it is known that co-expression of the binding partner can improve the 
solubility of the protein 153, co-expressing renin or prorenin together with the respective PRR 
construct was tested. For hsPRR (15-300), which showed weak soluble expression of the 
protein, the purification conditions were attempted to be improved, by changing the amount 
of salt, pH, adding detergent or using different buffers. None of these efforts resulted in 
soluble protein in sufficient amount and quality. All attempts are summarized in the construct 
table (see methods section, 3.1.9).  
 
Only a few proteins were found to be soluble and their expression was then scaled up in order 
to purify protein in sufficient amount and quality. These were hsPRR (170-303), hsPRR (101-
257) and hsPRR (166-257) (Figure 9) and the mmPRR (166-257), xlPRR (163-254), drPRR 
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(99-255) and drPRR (164-255). The purification and characterization of these soluble PRR 
proteins is described in the following sections. 
 
4.1.2. Expression of hsPRR (170-303) 
Hs PRR (170-303) was found to be soluble only when fused to a GST-tag (Figure 10 A, SN 
lane). The first purification step for this protein was therefore a GSH-Sepharose column. 
Following a series of washes to remove non-specifically bound proteins (Figure 10 A, lane 
W), Prescission protease digestion was then performed directly on the column. On-column 
digestion was chosen to prevent the GST-tag from non-specifically binding to the untagged 
protein (data not shown). The eluted, untagged protein was then additionally purified by size-
exclusion chromatography.  
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Figure 10. Purification of GST-tagged hsPRR (170-303).  
A) SDS-PAGE analysis of GSH-sepharose purification step. Lane contents: ni, uninduced cell lysate; in, induced 
cell lysate; SN, supernatant/soluble fraction; FT, GSH-sepharose flow-through; W, first wash; WO, wash-out 
(untagged hsPRR) fraction; E, eluate (of GST-tag); S, purified protein; M, marker. Arrows indicate bands 
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corresponding to the Prescission protease (PP), free GST-tag, and hsPRR (170-303). (B) Chromatogram of the 
hsPRR (170-303) run on a Superdex200 column. Below the trace a SDS-PAGE analysis of the corresponding 
fractions was performed (indicated by numbers). On the right, SDS-PAGE analysis of the final purified protein 
(A, pooled fractions 30-39) is shown. 
 
The elution profile of the Superdex 200 gel filtration column is shown in Panel B (Figure 10 
B). The elution profile was very broad, making the removal of contaminating proteins 
difficult. As a result, the pooled protein had several higher molecular weight contaminants 
and was estimated to be only 80 % pure (Figure 10 B, lane A). Typical yields of hsPRR (170-
303) were ~0.5 mg protein per 1 L of bacterial culture. 
 
4.1.3. Expression of hsPRR (101-257)  
Because hsPRR (170-303) was only 80 % pure and the yield was low, screening for soluble 
proteins was continued. The hsPRR (101-257) was found to be soluble in test-expressions.  
The first purification step for 6xHis hsPRR (101-257) was an immobilized metal ion affinity 
column (IMAC) (Figure 11 A). After extensive washing of the column (lane w), the bound 
protein was eluted with 150 mM imidazol (lane E) and the 6xHis tag was subsequently 
cleaved overnight (lane +PP). During the overnight cleavage, the sample was dialyzed against 
buffer without imidazol. In the second purification step, the cleaved hsPRR (101-257) was 
applied again onto the Talon column in combination with a GSH column. The untagged 
hsPRR (101-257) (in buffer without imidazol) passed through the column (lane 2. FT.), while 
contaminating proteins (lane E2) and GST Prescission Protease (lane E1) bound to the 
column. 
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Figure 11. Purification of the 6xHis-tagged hsPRR (101-257). 
A) SDS-PAGE analysis of IMAC purification. Lane contents: in, induced cell lysate; SN, supernatant/soluble 
fraction; FT, flow-through; W, wash fraction; E, eluate of hsPRR (101-257); M, marker; +PP, Prescission 
protease digest; 2. purification step, FT flow through fraction after cleavage, E1 elution from GSH column 
(control),  E2 elution from the Talon column (control). Arrows indicate bands corresponding to the Precission 
Protease (PP) and hsPRR (101-257). (B) Chromatogram of the hsPRR (101-257) run on a Superdex200 column. 
Directly below the trace SDS-PAGE analysis of the corresponding fractions (indicated by numbers) is shown. 
On the left SDS-PAGE analysis of the final purified protein (A, pooled fractions 30-39) is shown. 
 
The last purification step was a gel filtration column (Figure 11 B).  The sample eluted with 
two distinct peaks, however when analysed by SDS-PAGE these were found to consist only 
of hsPRR (101-257), indicating that the hsPRR (101-257) forms two different oligomeric 
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species. The protein was about 90 % pure and gave yields of about 2 mg per 1 L bacterial 
culture. 
4.1.4. Limited proteolysis of hsPRR (101-257) 
Conditions which favour homogenous and stable protein populations are most favourable for 
crystallization. To identify the structurally stable regions of soluble PRR, a limited proteolytic 
digestion approach was used. As flexible loops are more accessible by proteases and are thus 
preferentially cut, limited proteolysis can remove these flexible regions, creating shorter, 
stable constructs. The hsPRR (101-257) was incubated with several proteases (thermolysin, 
subtilisin, chymotrypsin and trypsin) at different dilutions and temperatures.  Interestingly, 
digestion with all four proteases resulted in the appearance of a ~ 14 kDa fragment. Of the 
four proteases, most distinct results were obtained with digestion with chymotrypsin 1:1000 at 
37 °C (Figure 12), where a second band of ~10 kDa was observed. The two observed bands 
(Figure 12, red box, arrows 1 and 2), were then cut from the gel and identified by mass 
spectrometry. The mass spectrometry data of the two samples (Figure 12, arrow 2) identified 
a hsPRR fragment with a molecular weight of approximately 12 kDa. The sequence coverage 
was around 90 %. The mass spectrometry data was compared with the secondary structure 
prediction analysis (described above) and the known peptide cleavage site, and on the basis of 
this, three new constructs covering this fragment were designed. 
 
 
Figure 12. Proteolytic digestion of hsPRR (101-257).  
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SDS-PAGE analysis of hsPRR (101-257) incubated with the four different proteases (thermolysin, subtilisin, 
chymotrypsin, trypsin). Digestion with chymotrypsin 1:1000 at 37 °C resulted in two stable fragments (red box, 
arrows 1 and 2). These were subsequently analyzed by mass spectrometry. S untreated sample, M marker 
 
4.1.5. Expression of hsPRR (166-257) 
Based on the limited proteolysis experiment, three new constructs were cloned. Only one of 
these, hsPRR (166-257), was found to be soluble and thus only expression of this protein was 
scaled up. 
 
The 6xHis hsPRR (166-257) was purified by an IMAC. The bound protein was eluted and the 
tag was cleaved overnight and dialyzed against buffer without imidazol. To remove the GST-
tagged Prescission protease and contaminating proteins, the sample was applied again on the 
Talon column in combination with a GSH column (Figure 13 A). The sample was applied on 
a gel filtration column (Figure 13 A) and eluted in one distinct peak. The protein was about 95 
% pure and gave yields of about 8 mg per 1 L bacterial culture. 
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Figure 13. Purification of the 6xHis-tagged hsPRR (166-257). 
 A) SDS-PAGE analysis of IMAC purification. Lane contents: in, induced cell lysate; SN, supernatant/soluble 
fraction; FT, flow-through; W1, wash fraction; W2, wash fraction with 10mM imidazol E, eluate of hsPRR (166-
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257); M, marker; +PP,  Prescission protease digest; 2. purification step, FT flow through fraction after cleavage, 
Arrows indicate bands corresponding to the Precission Protease (PP) and hsPRR (166-257). (B) Chromatogram 
of the hsPRR (166-257) run on a Superdex75 column.  
 
4.1.6. Expression of PRR proteins from different species  
Consequently, the human constructs 101-257 and 166-257 were tried to adopt to the different 
available species by using the amino acid alignment results described previously. During test 
expressions only a few of these constructs were soluble. MmPRR (166-257), xlPRR (163-
254), drPRR(164-255) and drPRR(99-255) were expressed and purified. All of these proteins 
gave rather low amounts of protein (approximately 0.5 mg per 1 L bacterial culture), and 
protein preparation were only 70-80 % pure.  
 
4.2. Characterization of purified hsPRR proteins 
4.2.1. Characterization of hsPRR (170-303) 
4.2.1.1. Secondary structure determination of hsPRR (170-303)  
hsPRR (170-303) could be purified in mg amounts. The correct fold of a protein is necessary 
for its function. Therefore, the secondary structure of hsPRR (170-303) was analyzed by 
circular dichroism (CD). Figure 14 A shows the CD spectrum for hsPRR (170-303) measured 
at four different temperatures. At room temperature, the spectrum reflects a typical alpha 
helical fold, with minima at 222 nm and 208 nm. The data was fitted with an algorithm 
provided by Sandro Keller (TU Braunschweig, Germany) to estimate the percentages of folds 
(alpha-helical, beta-sheet, random coil; Figure 14 A table). This analysis showed that the 
hsPRR (170-303) has an almost exclusively alpha helical fold. At 4 °C and 20 °C the alpha 
helical content was 84 % and 65 %, respectively. Analysis of the structural stability of the 
protein was also performed. Figure 14 B shows the melting curve of hsPRR (170-303). The 
ellipticity of the protein was monitored at a wavelength of 222 nm with a constant increase in 
temperature of 1 °C per minute. The calculated melting temperature is 45.3 °C, which is 
relatively low 154. Above this temperature, the protein unfolds and precipitates. 
 59
4. Results
 
0 20 40 60 80 100
-30
-20
-10
0
Tm=45,3°C
B °C
I(
au
)
200 210 220 230 240 250 260
-30
-20
-10
0
10
20
4°C 20°C 40°C 60°C
f a-helix 84% 65% 99% 37%
f b-sheet 7% 13% 0% 0%
f b-turn 0% 6% 1% 63%
f random coil 9% 16% 0% 0%
  (nm)
[ ]
(k
°c
m
2 /d
m
ol
)
A
 
Figure 14. Secondary structure analysis of hsPRR (170-303) by circular dichroism (CD) spectrometry.   
A) The CD spectra of the hsPRR(170-303) was measured at four different temperatures (4 °C blue, 20 °C light 
blue, 40 °C green, 60 °C orange). The proportion of α-helix, β-sheet, β-turn and random coil were estimated and 
are listed in the table. (B) Melting curve analysis at 222nm with temperature increments of 1 °C per minute.  
 
4.2.1.2. Interaction of hsPRR (170-303) with (pro)renin  
Next it was investigated if hsPRR (170-303) bound to its known ligands. It was previously 
published that full-length PRR binds to renin and with even higher affinity to prorenin 1, 40. 
The (pro)renin binding site has not yet been identified, except that it is located on the 
extracellular domain.  Human renin or prorenin was incubated in equimolar amounts with 
GST-tagged PRR (170-303). The two supposed interaction partners were then incubated with 
GSH sepharose. The unbound protein was washed from the GSH material and the bound 
protein was eluted. Figure 15 shows that neither renin (A) or prorenin (B) was pulled-down 
with the PRR construct, indicated by the lack of visible bands in the bound fraction.  This 
suggests that in this assay, renin and prorenin do not bind with high affinity to GST-tagged 
hsPRR (170-303). 
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Figure 15. Interaction study of GST hsPRR (170-303) with renin or prorenin.  
SDS-PAGE analysis of the pull-down assay. On the left side of the SDS-PAGE the controls 6xHis renin (A) or 
prorenin (B) and the GST hsPRR (170-303) (input) are shown. On the right side are the bound and unbound 
samples. Arrows indicate the position of GST hsPRR (170-303) and renin or prorenin. 
 
4.2.2. Characterization of hsPRR (101-257) 
4.2.2.1. Secondary structure determination of hsPRR (101-257) 
hsPRR (101-257) was of good solubility and could be purified to high amounts and quality. 
The secondary structure of hsPRR (101-257) was also analyzed by circular dichroism. Since 
hsPRR (170-303) revealed an overall alpha helical fold, it was of interest to see if this protein 
gave similar results. Figure 16 A shows the CD spectra for hsPRR (101-257) with a typical 
alpha helical fold, with minima at wavelengths of 222nm and 208 nm. For temperatures 
between 4 °C and 44 °C the percentage of alpha helices is between 62 % and 92 % (Table 16 
A). With increasing temperatures, the composition changes from an overall alpha helical fold 
to a higher percentage of random coil structure Table A. After first heating the sample to 94 
°C and decreasing the temperature back to 4 °C, the protein seems to be predominantly 
structured (Figure 16 A purple line), indicating that it is able to re-fold after thermal 
denaturation. However, the calculated percentages of the folds in this sample are quite 
different when compared to the spectra collected at 4 °C and 24 °C, and shows a relatively 
high content of random coil. Since the melting curve displayed an almost linear increase 
instead of a typical sigmoidal curve, the melting point could not be determined. These results 
indicate that hsPRR (101-257) has increased thermal stability.  
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Figure 16. Secondary structure analysis of hsPRR (101-257) by circular dichroism (CD) spectrometry. 
A) CD spectra of the hsPRR (101-257) were measured at 6 different conditions (4 °C blue, 24 °C light blue, 44 
°C green, 64 °C orange, 94 °C red, 4 °C after melting purple). The proportion of α-helix, β-sheet, β-turn and 
random coil were estimated and are listed in the table. (B) Melting curve analysis at 222 nm with temperature 
increments of 1°C per minute is shown.  
 
4.2.2.2. Interaction study of hsPRR (101-257) with (pro)renin   
Next it was asked whether hsPRR (101-257) can bind to renin or prorenin. To address this, 
the same GST pull down approach as described before was used. Human renin and prorenin 
were incubated with GST-tagged hsPRR (101-257), thus allowing the complex to be pulled 
down with GSH sepharose. Figure 17 shows the result of the pull-down.  
 
 
Figure 17. Interaction study of GST hsPRR (101-257) with renin or prorenin. 
SDS-PAGE analysis of the pull-down assay. On the left side of the SDS-PAGE are the controls renin (A) or 
prorenin (B) and the GST hsPRR 101-257 (input). On the right side are the bound and unbound samples. Arrows 
indicate the position of GST hsPRR (101-257) and renin or prorenin. 
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Renin (A) and prorenin (B) were found solely in the unbound fraction, and GST-tagged 
hsPRR (101-257) in the bound fraction. This result indicates that under these conditions, this 
short construct is not able to bind to renin or prorenin. 
 
4.2.2.3. Analysis of the oligomerization of hsPRR (101-257) 
Results from the purification of hsPRR (101-257) showed that this protein eluted in two peaks 
from gel filtration column. SDS-PAGE revealed that these peaks only contain hsPRR (101-
257) and do not consist of contaminating proteins (see 3.1.3.). This suggests the presence of 
two oligomeric species in the sample. To analyze the molecular weight of the sample right-
angle light-scattering (RALS) was used.  In this experiment, a refractive index, UV and a 
RALS detector are set-up in-line with a gel filtration column (Superdex 200 10/300). With 
this, the average molecular weight of the sample can be estimated. The calculated molecular 
weight (Figure 18, black line) shows two different plateaus for the two peaks, reflecting 
different molecular weights. Closer analysis showed that the first peak has a calculated 
average molecular weight of 96 kDa. As hsPRR has a theoretical molecular weight of 18.44 
kDa, this peak represents an oligomer of 5-6 subunits (pentamer or hexamer). This 
experiment was repeated five times, resulting in an average molecular weight of 102 ± 11 
kDa. The second peak was estimated by RALS to have an average molecular weight of 26 
kDa. In five different experiments this peak had an average molecular weight of 23 ± 5 kDa. 
This peak therefore seems to be predominantly monomeric. By re-applying the concentrated 
fractions of either peak 1 or peak 2, the protein still eluted in two distinct peaks, each having 
the same average molecular weights as calculated previously. Also, when analysed at 
different concentrations varying from 2 to 10 mg/ml, two peaks were observed. These results 
indicate that hsPRR (101-257) forms a monomer and an oligomer in solution, which are in 
equilibrium. 
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Figure 18. Right angle light scattering (RALS) analysis of the hsPRR (101-257). 
200µg of hsPRR (101-257) was used for analysis. The refractive index (blue line) and the calculated molecular  
weight (black line) are depicted. (A) HsPRR (101-257) eluted in two peaks with different apparent molecular 
weights. Single analysis of the first peak giving a calculated MW of 96 kDa and single analysis of the second 
peak with a determined MW of 26 kDa 
 
To further investigate the oligomerization of hsPRR (101-257), analytical ultracentrifugation 
was used. Sedimentation velocity is an analytical ultracentrifugation experiment, which 
measures the rate at which molecules move in response to the centrifugal force. The time 
course of sedimentation provides information about the molecular mass and the shape of 
molecules that is described by the sedimentation coefficient, Svedberg (S). Figure 19 shows a 
typical sedimentation time course and the fitted data.  
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Figure 19. Sedimentation velocity analysis of hsPRR (101-257). 
Sedimentation velocity of 2 mg/mL hsPRR (101-257) with radial scans collected in 10 min intervals (circles) 
and theoretical fits of the data (lines). For clarity, only every fourth scan is shown. 
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Figure 20 shows the sedimentation coefficient distribution for hsPRR (101-257). At 
concentrations of 1 and 0.5 mg/ml, only one species is present in solution with a 
sedimentation coefficient between 2.5 S and 2.6 S. This was estimated to correspond to a 
molecular mass between 26 and 29 kDa using the program SEDFIT, indicating that 
predominantly monomers are present in solution. At a concentration of 2 mg/ml, an additional 
peak was observed in the distribution. This corresponds to an oligomeric species with a 
sedimentation coefficient of 4.04 S and an estimated molecular mass of 56 kDa.  These results 
are in agreement with the RALS results, where the existence of a monomer and an oligomer 
was observed.  Although the estimated molecular weight for the oligomeric peak measured 
with RALS was around ~100 kDa. Sedimentation velocity analysis does not take into account 
the shape of a molecule, which might influence its sedimentation behaviour; therefore the 
RALS results are more reliable. But sedimentation velocity analysis gave additional 
information about the concentration dependence of the oligomerisation of hsPRR (101-257) 
below 2 mg/ml, as the RALS experiments were only performed at concentrations of 2 mg/ml 
and above.  
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Figure 20. Sedimentation coefficient distribution of hsPRR (101-257) at different protein concentrations. 
The hsPRR (101-257) was analyzed at 0.5 (red line), 1 (blue line) and 2 mg/mL (green line). The average 
sedimentation coefficient and molecular mass of the peaks are shown in the table.  
 
For protein structure determination, a homogenous sample is favourable because the presence 
of several different species in the sample reduces the likelihood of crystallization. As shown 
in Figures 18 and 20 above, at protein concentrations above 2 mg/ml hsPRR (101-257) exists 
in a monomer/oligomer equilibrium. As high protein concentrations are needed for structural 
studies, this heterogeneous equilibrium condition is not likely to results in crystal formation. 
To investigate if buffer conditions affect the oligomerization of hsPRR (101-257), 
sedimentation velocity experiments were performed at different pHs. The protein sample was 
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at a concentration of 2 mg/mL in a buffer containing 150 mM NaCl and 20 mM of the 
respective buffer. Figure 21 shows the sedimentation coefficient distributions for hsPRR 
(101-257) at each different pH. For improved clarity, the six different conditions are shown in 
two graphs. At pH 6 the protein precipitated, indicated by a loss in adsorption of the sample 
(data not shown), therefore this condition could not be measured. At pH 6.5 (MES buffer), a 
broad distribution was observed. This probably reflects the beginning of sample precipitation. 
At pH 7 and pH 7.5 (both in HEPES), the expected monomer/oligomer peaks, as described in 
Figure 20 above, were seen. However, above pH 8 (Tris pH 8, Tris pH 8.5 and Glycine pH 9) 
only one peak was visible. The sedimentation coefficient for this peak varied from 2.28 to 
2.37 S, which represents a molecular mass of approximately 24 kDa. Therefore, under these 
conditions (i.e. above pH 8) hsPRR (101-257) appears to be predominantly monomeric. 
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Figure 21. Sedimentation coefficient distributions of hsPRR (101-257) at different pH values. 
Left panel: pH 6.5 (pink), pH 7.5 (purple), pH 8.5 (green). Right panel: pH 7.0 (purple), pH 8 (blue), pH 9 
(green). The average sedimentation coefficients and molecular mass of the peaks are shown in the table. Because 
of the broad distribution at pH 6.5 these parameters could not be determined (n.a.) For clarity, data are depicted 
in two graphs. 
 
 66
4. Results
 
The effect of buffer composition on the oligomerization of hsPRR (101-257) was also 
investigated. Figure 22 shows the sedimentation coefficient distribution for hsPRR (101-257) 
at pH 8 in Tris and HEPES buffer. Under both conditions, hsPRR (101-257) sedimented as 
one peak with an average sedimentation coefficient of 2.3 S and 2.45 S for Tris and HEPES, 
respectively. This indicates that under these conditions, hsPRR (101-257) is predominantly 
monomeric and that the oligomerization observed is dependent on the pH of the buffer, and 
not on the composition. Above pH 8 it, exists as a monomer, while below pH 7.5 it exists in a 
monomer/oligomer equilibrium. 
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Figure 22. Sedimentation velocity analysis of hsPRR (101-257) at pH 8 in HEPES (red) or Tris (blue) 
buffer. The average sedimentation coefficients and molecular mass of the peaks are shown in the table.  
 
As shown above, changing the pH resulted in a drastic shift from a single monomer in 
solution to monomer/oligomer equilibrium.  One possibility is that this pH change induces the 
protein to unfold. Therefore, secondary structure of hsPRR (101-257) was analyzed in 
different buffers (20 mM buffer, 150 mM NaFl), varying from pH 6.5 to pH 8 using CD 
spectroscopy (Figure 22). Under all conditions, hsPRR (101-257) had a predominantly alpha-
helical fold, of approximately 73 % to 76 %.  This indicates that changing the pH and the 
buffer composition has no dramatic effect on the secondary structure of hsPRR (101-257). 
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Figure 23. Secondary structure of hsPRR (101-257) in different buffer conditions. 
CD spectra of hsPRR (101-257) were measured at 20 °C with different buffers (20 mM) and pH (Mes pH 6.5 in 
blue, HEPES pH 7.5 in red, HEPES pH 8 in green, HEPES pH 8 in orange). The amount of α-helix, β-sheet, β-
turn and random coil were estimated and are listed in the table. 
 
4.2.3. Characterization of hsPRR (166-257) 
HsPRR (166-257) was designed after performing a limited proteolysis experiment (section 
3.1.4). This protein could be purified to high purity and yield.  
 
To analyze if this protein is folded, secondary structure determination of hsPRR (166-257) 
was performed by circular dichroism. Figure 24 A shows that all spectra have a typical alpha 
helical shape with two minima.  The hsPRR (166-257) has an alpha helical fold content of 
approximately 80 %. The melting temperature was determined to be 53.7 °C (B). The hsPRR 
(166-257) was able to reversibly refold after thermal unfolding and had almost the same alpha 
helical composition as before unfolding. These results indicate that hsPRR (166-257) has a 
very high thermal stability. 
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Figure 24. Secondary structure analysis of hsPRR (166-257) by circular dichroism (CD) spectrometry.  
A) CD spectra of hsPRR (166-257) were measured at 4 different conditions (4 °C blue, 20 °C red, 4 °C after 
melting green, 20 °C after melting orange). The proportion of α-helix, β-sheet, β-turn and random coil were 
estimated and are listed in the table. (B) Melting curve analysis at 222 nm with temperature increments of 1 °C 
per minute.  
 
As hsPRR (101-257) was found to be in a monomer/oligomer equilibrium in solution, it was 
of interest to analyse the molecular weight of the hsPRR (166-257) and to find out if this 
protein behaved similarly. To determine the molecular weight of this construct, right-angle 
light-scattering was performed as described previously. Figure 25 A shows that the hsPRR 
(166-257) eluted in one peak from gel filtration. The theoretical molecular weight is 11.17 
kDa while the experimentally observed one by RALS is 18.32 kDa. The calculated molecular 
weight in this peak ranged from 10 to 27 kDa and the peaks appeared to be unsymmetrical, 
with a shoulder on one side. Thus, it is possible that in this sample both monomers and dimers 
are present.  To investigate this further, the protein was incubated with a cross-linker, BS3, to 
covalently cross-link the putative dimer, which could then be analyzed by SDS-PAGE (see 
3.3.10.) Figure 25 B shows, in the presence of the cross-linker, the appearance of a dimeric 
band. By increasing the incubation time for cross-linking, increased amounts of dimeric 
sample were not observed. Instead higher oligomers appeared that were possibly due to 
unspecific cross-linking (data not shown).  
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Figure 25. (A) Right-angle light-scattering (RALS) analysis of hsPRR (166-257). 
The refractive index (blue line) and the calculated molecular weight (black line) are depicted. (B) Cross-linking 
of hsPRR (166-257) with BS3. SDS-PAGE analysis of hsPRR (166-257) before and after cross-linking. Arrows 
mark the position of monomeric and dimeric hsPRR (166-257). 
 
At this point, it was considered that hsPRR (166-257) existed in a monomer/dimer 
equilibrium. As this condition is not favourable for crystallisation, constructs were designed 
where potential unstable regions were removed, and an additional helix was added or deleted 
based on results from the secondary prediction analysis. These constructs were hsPRR (166-
269) and hsPRR (174-257). Analysis of the sequence of hsPRR (166-257) revealed a pattern 
with a high amount of charged amino acids (position 201-207). As charged residues often 
have a negative influence on crystallization, these amino acids were mutated to alanines 
(KHLAKDH to AAAAAAA), resulting in the construct hsPRR (166-257) 201AAAAAAA207.  The 
three new constructs were first analyzed for their molecular weight by right-angle light-
scattering.  All constructs eluted in a single peak (Figure 26). The hsPRR (166-257) 
201AAAAAAA207 has an average calculated molecular weight of 19.52 kDa (Figure 26 A), hsPRR 
(166-269) of 19.61 kDa (Figure 26 B) and hsPRR (174-257) of 15.72 kDa (Figure 26 C). For 
all samples the experimental molecular weight varies for the single peaks from 10 to 30 kDa 
and the peaks were again non-symmetric, suggesting that these proteins may also be non-
homogenous. The theoretical molecular weight is 10.36 kDa for hsPRR (174-257), 10.84 kDa 
for the hsPRR (166-257) 201AAAAAAA207 and 12.46 kDa for hsPRR (166-269).  Based on the 
RALS results, it appeared that all three constructs are also in a monomer/dimer equilibrium. 
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Because of the low purity and quality, working with hsPRR (166-269) and hsPRR (174-257) 
was stopped. 
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Figure 26. Right angle light scattering (RALS) analysis of hsPRR proteins.  
The refractive index (blue line) and the calculated molecular weight (black line) are depicted.  (A) The hsPRR 
(166-257) 201AAAAAAA207 has an average calculated molecular weight of 19.52 kDa. (B) The hsPRR (166-29) has 
an average calculated molecular weight of 19.61 kDa and (C) the hsPRR (174-257) has an average molecular 
weight of 15.72 kDa. 
 
The secondary structure of hsPRR (166-257)201AAAAAAA207 was analyzed by circular 
dichroism. The hsPRR (166-257)201AAAAAAA207 has an overall alpha helical fold (Figure 20). 
Comparison of the wild-type with the mutant construct shows that both have an almost 
identical protein fold in the CD spectra (alpha helical content of 77 % vs. 80 %). 
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Figure 27. Secondary structure analysis of hsPRR (166-257)201AAAAAA207 by circular dichroism (CD).  
The proportion of α-helix, β-sheet, β-turn and random coil were estimated and are listed in the table. For 
comparison, the proportions of α-helix, β-sheet, β-turn and random coil of the hsPRR (166-257) are also listed. 
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To determine if the hsPRR (166-257) proteins have the same molecular mass and form 
monomers or dimers, the WT and mutant sample were analyzed by sedimentation velocity 
ultracentrifugation. Figure 28 show that both proteins have similar sedimentation coefficient 
distributions. The sedimentation coefficient for the WT sample is 2.07 S and for the mutated 
sample 2.1 S, and the respective estimated molecular mass of 20.39 kDa and 20.91 kDa are 
almost identical. Insertion of alanines into hsPRR (166-257) did not prevent dimerization, as 
predicted. Therefore, all following analyses were performed with the WT hsPRR (166-257). 
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Figure 28. Sedimentation velocity analysis of hsPRR (166-257) (red line) and hsPRR (166-257)201AAAAAAA207  
(blue line). The average sedimentation coefficients and molecular masses of the peaks are shown in the table. 
 
As decribed above, hsPRR (101-257) oligomerized at concentrations above 2 mg/mL and in a 
pH dependent (below pH 8) manner. In the next experiments, it was investigated, if the 
hsPRR (166-257) behaved in a similar fashion. Samples were analyzed by sedimentation 
velocity centrifugation at different protein concentrations using varying buffer conditions. 
hsPRR (166-257) was analyzed at concentrations between 0.3 to 1.2 mg/mL. These 
concentrations were choosen to have the same molar concentration as for the hsPRR (101-
257). For all three concentrations, only one peak in the sedimentation coefficient distribution 
was present (Figure 29). They all have similar sedimentation coefficients between 2.07 and 
2.15 S and calculated molecular masses between 20.73 and 21.76 kDa. Thus hsPRR does not 
oligomerize in a protein-concentration dependent fashion. 
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Figure 29. Sedimentation velocity analysis of the hsPRR (166-257).  
The hsPRR (166-257) was analyzed for 0.3 (green line), 0.6 (red line) and 1.2 mg/ml (blue line). The 
sedimentation coeffincients and the molecular masses of the peaks were calculated and are depicted in the table. 
 
From sedimentation velocity, right-angle light-scattering and gel filtration experiments it 
could not accurately be determined if hsPRR (166-257) is either a monomer or a dimer in 
solution, or if both species are present in equilibrium state. To more accurately determine the 
oligomerisation state of hsPRR (166-257), sedimentation equilibrium ultracentrifugation 
experiment was performed. In this analytical ultracentrifugation experiment, the protein 
reaches a steady-state concentration distribution where the centrifugal force is balanced by the 
opposing diffusion force. This method is thereby independent of the shape of the protein and 
directly reports the molar mass of the sample. hsPRR (166-257) was analysed at six different 
concentrations and at three different speeds. Figure 30 depicts the radial absorbance data 
(dots) and the fits to the data (lines) at the various concentrations and speeds. The data and fits 
demonstrate the typical concave distribution of the sample due to it reaching equilibrium. 
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Figure 30. Sedimentation equilibrium centrifugation runs of the hsPRR (166-257).  
The hsPRR (166-257) was analyzed for the following concentrations: 0.25, 0.5, 0.75, 1, 1.5, 2mg/ml. 
Absorbance scans were taken after the sample reached equilibrium at 20,000 (green), 25,000 (blue) and 35,000 
(red) rpm. The absorbance data (dots) was fitted (lines) to determine the molar mass of the sample. 
 
By applying a global fit to all data, an apparent average molecular mass of the samples of 
17.96 kDa was determined.  As the theoretical molecular weight of hsPRR (166-257) is 11.17 
kDa, the results from the global fit suggests the presence of both monomer and dimer in 
solution.  Since the applied global fit did not take into account a concentration dependent 
association, the data was then analyzed separately at each concentration. Figure 31 depicts the 
calculated molecular mass at each concentration. The black lines indicate the molecular 
weight of a monomer (11.17 kDa) and a dimer (22.34 kDa). The molecular masses calculated 
were: 16.6 kDa at 0.25 mg/ml, 18.7 kDa at 0.5mg/ml, 17.9 kDa at 0.75 mg/ml, 19.3 kDa at 
1mg/ml, 19 kDa at 1.5 mg/ml and 17.6 kDa at 2 mg/ml. These apparent molecular masses lie 
in between the calculated monomeric and dimeric molecular weights. It also appears that the 
molecular mass increases with increasing concentration. Therefore, from this data it was 
concluded that hsPRR (166-257) exists in a monomer/dimer equilibrium. It would be 
expected for a real monomer/dimer equilibrium that at lower concentrations the molecular 
mass of the system would decrease to the molecular weight of the monomer. However, due to 
the detection limits with this instrument, the concentrations could not be decreased below 
0.25 mg/ml.  
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Figure 31. Apparent molecular masses for hsPRR 166-257 calculated by sedimentation equilibrium.  
The hsPRR (166-257) was analyzed at  protein concentrations at 0.25, 0.5, 0.75, 1, 1.5 and 2mg/ml. The black 
lines indicate the monomeric and dimeric molecular weight for hsPRR (166-257). 
 
4.2.3.1. Interaction study of hsPRR (166-257) with renin 
hsPRR (170-303) and hsPRR (101-257) did not bind to either renin or prorenin in a GST pull-
down assay (see Figures 15 and 17). Whilst expressing GST-tagged hsPRR (166-257), the 
protein was soluble, but during purification the tag showed a tendency to be cleaved from the 
fusion protein without the use of a protease (data not shown). Thus, a GST pull-down assay 
was not possible. Instead, the interaction of hsPRR (166-257) with renin was analyzed by 
sedimentation velocity.  The hsPRR (166-257) was incubated in equimolar amounts with 
renin. Figure 32 shows the sedimentation coefficient distribution hsPRR (166-257) (blue) and 
renin (green) alone, and when incubated together (red). If the two proteins bound, a shift in 
the sedimentation coefficient distribution would be expected. Alone, hsPRR (166-257) has a 
sedimentation coefficient of 2.07 S and renin has a sedimentation coefficient of 3.56 S. These 
sedimentation coefficients correspond to a molecular mass of 20.39 and 45.17 kDa, 
respectively (renin has a calculated molecular weight of 42 kDa). When incubated together, 
no shift in the sedimentation coefficient distribution is observed. The resulting distribution is 
broad, and overlays the single distribution peaks of the proteins sedimented alone. This 
indicates that under these conditions, renin does not bind to hsPRR (166-257).  
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Figure 32. Sedimentation velocity analysis of hsPRR (166-257) incubated with renin. 
Both samples are shown alone (renin green, hsPRR (166-257) blue) and when incubated together in equimolar 
concentration (red). The sedimentation coefficients and molecular mass of renin and hsPRR (166-257) were 
calculated and are shown in the table. 
 
4.2.4. Characterization of homologous PRR from different species 
PRR homologs from other available species, like mouse, zebrafish and frog, were also 
expressed and purified, using a multiple sequence alignment with the boundaries with the 
human PRR (101-257) and (166-257). The following proteins were soluble, but could be 
obtained only in rather low amount and quality:  mmPRR (166-257), xlPRR (163-254), 
drPRR (164-255) and drPRR (99-255).  The secondary structure of these proteins was 
analyzed by circular dichroism. All proteins showed a typical alpha helical CD spectrum (see 
figure 33). The short proteins from mouse [mmPRR (166-257)], frog [xlPRR (163-254)] and 
zebrafish [drPRR (164-255)] had ~80% alpha helical content. This is in good agreement with 
the human proteins; hsPRR (166-257) had ~80% and hsPRR (101-257) had ~70% alpha 
helical content. The only longer (101-257) construct that was soluble was from zebrafish 
[drPRR (99-257)] which had a calculated proportion of alpha helical content of 60%, which 
again is similar to the respective human protein.  
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Figure 33. Secondary structure of different PRR constructs by circular dichroism (CD) spectroscopy.   
A) CD spectra measured at 20 °C showing a typical alpha helical for mmPRR (166-257) (orange), xlPRR (163-
254) (green), drPRR (164-255) (red) and drPRR (99-255) (blue). The proportion of α-helix, β-sheet, β-turn and 
random coil structure were estimated and are listed in the table.  
 
As described above, in solution hsPRR (101-257) is in a monomer/oligomer equilibrium and 
hsPRR (166-257) is in a monomer/dimer equilibrium (Figure 20 and 31). The oligomeric state 
of the homologous proteins from the different species were also investigated by right-angle 
light-scattering. Figure 34 shows the elution of the samples in one peak. MmPRR (166-257) 
(Figure 34 A) had a calculated molecular weight of 54.17 kDa. Taking into account the 
theoretical molecular weight, this indicates that this protein is a tetramer or pentamer. The 
xlPRR (163-254) (Figure 34 B) and the drPRR (164-255) (Figure 34 C) both appeared to be 
dimers, but the data was relatively disperse and the peaks were not homogenous for the 
dimeric molecular weight. The drPRR (99-257) (Figure 34 D) appeared to have a molecular 
weight of 32.04 kDa, indicating a dimer.  
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Figure 34. Right angle light scattering (RALS) analysis of PRR constructs.  
The refractive index (blue line) and the calculated molecular weight (black line) are plotted. The theoretical and 
calculated molecular weights are shown below the graph. (A) mmPRR (166-257) (B) xlPRR (163-254) (C) 
drPRR( 164-255) (D) drPRR (99-255)  
 
4.3. Structural studies 
4.3.1. Crystallization trials 
One of the major aims of this thesis was to determine the structure of hsPRR by X-ray 
crystallography. However, only a few of the PRR constructs were soluble and could be 
produced in sufficient amount and quality. Therefore, crystallization trials were only 
performed with hsPRR (170-303), hsPRR (101-257), hsPRR (166-257), hsPRR (166-257 
201AAAAAA207) and drPRR (164-255). All proteins were screened for initial hits on 96-well 
plates using predesigned crystal screens. Approximatly, 20,000 initial conditions were 
screened for each of the different PRR constructs. Screens were performed at either 4 °C or 
20 °C, using different protein stock concentrations. None of these initial screens resulted in 
the formation of crystals. Manual screens were then performed. Thereby, different 
precipitants, pH conditions and salt additives were tested. Results of these screens were then 
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considered for the design of the additional manual screens. Other variables tested include 
crystal trials where low concentrations of proteases were added. Also, methylating the 
proteins was tried, as this has been shown previously to improve the likelihood of crystal 
formation 155.  Unfortunately, all of these attempts were unsuccessful and no protein crystals 
were obtained.  
 
4.3.2. Nuclear magnetic resonance (NMR) spectroscopy 
As all of the crystallization screens tested did not result in the formation of protein crystals, 
solution-state nuclear magnetic resonance spectroscopy (NMR) was performed, as another 
method to obtain structural information.  For NMR studies of proteins it is necessary to label 
the sample with the isotopes 13C and 15N, as the naturally occurring isotopes are not NMR 
active. Therefore hsPRR (166-257) was single and double labelled with 13C and 15N isotopes. 
For the incorporation of these isotopes into the protein, it is essential to grow the bacteria in 
minimal medium. As not all constructs can be expressed in minimal media, a small scale 
expression assay was first tested (Figure 35). The best protein expression of hsPRR (166-257) 
in minimal media was achieved when protein expression was induced at a cell density of 
OD600nm = 0.4. A larger scale protein expression and purification was then performed, 
resulting in a yield of ~3 mg per 1 L of minimal medium with a final purity of ~95 %. 
 
 
 
Figure 35. Test expression of hsPRR (166-257) in minimal medium  
The optimal induction time was tested. IPTG was added at the indicated optical densities. Lane contents: ni not 
induced, in induced, SN supernatant, M marker 
 
The single and double labelled hsPRR (166-257) was analysed by NMR at a concentration of 
1 mM in 100 mM NaCl and 50 mM phosphate buffer pH 7.5 at 20 °C. First, a one-
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dimensional 1H-NMR spectrum was recorded to determine if the unlabelled hsPRR (166-257) 
is NMR suitable. Figure 36 A shows the one-dimensional spectrum. The protein is folded, 
indicated by a good overall dispersion of the observed resonances. The resonances in the 
range of 8.5 to 10 ppm for the amide protons and the resonances in the range of 0.7 to 0 for 
the methyl groups in the 1H-NMR spectrum indicate well folded protein.  Following this, a 
two-dimensional NMR experiment was performed. Figure 36 B shows a heteronuclear single-
quantum correlation spectroscopy (HSQC) spectrum of the single labelled hsPRR (166-257), 
with correlated frequencies for the 1H–15N.  In theory, each resonance in the spectrum 
represents a bonded N-H pair, with its two coordinates corresponding to the chemical shifts of 
each of the H and N atoms. Most of the peaks for hsPRR (166-257) are  around the 8ppm 
area, typical for alpha helical proteins 156. Key to the determination of protein structure by 
NMR is the assignment of amino acids to the peaks. It was assumed from the one-dimensional 
experiment that double labelling (13C, 15N) of the samples could result in better spectra.  
Despite having recorded three-dimensional spectra with double labelled samples an 
assignment was not possible. One reason for this is the poor dispersion (i.e. overlapping) of 
the peaks in the area at 8ppm area, which makes assignment difficult. Additionally 
problematic is the fact that hsPRR (166-257) only has a few aromatic residues that give 
unique peaks, which are easy to assign. 
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Figure 36. Structural investigation of hsPRR (166-257) with nuclear magnetic resonance (NMR).  
A) One dimensional 1H-NMR spectrum of unlabelled hsPRR (166-257) (B) 1H–15N HSQC spectrum of single 
labelled hsPRR (166-257).  
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4.4. Function of PRR in T cells 
In the first part of this PhD thesis the in vitro characteristics of the PRR were examined. For 
the second part the role of the PRR in an in vivo system were analyzed. The role of the PRR 
for T cell maturation in a mice model was examined. 
 
4.4.1. Conditional PRR knock-out model  
To test the hypothesis that PRR plays a role in T cell function, maintenance and development 
a conditional knock-out (KO) model was used (Figure 37). To generate T cell specific KO 
mouse, the PRR gene was targeted by homologous recombination using a construct in which 
exon 2 of the PRR was flanked by loxP sites.  Female heterozygous loxP PRR mice were 
mated with male heterozygous Cre mice. T cell specificity was achieved by using a Cre 
recombinase under the control of the LCK promoter. LCK is expressed solely in T cells and 
expression starts early in development at the DN3 stage. Since the PRR gene is localised on 
the X chromosome, male conditional KO (cKO) mice were obtained in the first offspring 
generation.  
 
Figure 37.Targeting strategy for the conditional KO of the PRR in T cells.  
To generate T cell specific PRR KO mice, female mice bearing a loxP flanked PRR gene were mate with male 
mice expressing the Cre transgene under the control of the LCK promoter.  
 
To confirm the specific deletion of the PRR gene, genomic DNA was isolated from several 
tissues and analysed by PCR. If the floxed PRR was excised by the Cre recombinase a shorter 
PCR fragment for the PRR (326 bp) would be expected. In tissues without the deletion, a full 
length PRR PCR fragment of 1426 bp is expected. Figure 38 shows the PRR PCR fragments 
of different tissues from cKO mice. In liver, lung and kidney the PRR is not excised and only 
the 1426 bp band is apparent. Also in the spleen, only full length DNA for PRR is present. 
The spleen is a tissue that is composed of several cell types, including B cells but also T cells. 
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Only in thymocytes (which are almost exclusively T cells) the PRR is deleted, confirmed by 
the short PRR DNA fragment. 
 
Figure 38. Excision of  exon 2 of PRR.  
Agarose gel of PCR fragments. Genomic DNA of lung, liver, kidney, spleen and thymocytes was analyzed for 
the deletion of the PRR. Tissues or cells without the deletion of exon 2 showed a longer PCR fragment of 1426 
bp. Excision of the PRR results in a shorter PCR fragment of 326 bp. 
 
Additionally, RNA was isolated from diverse tissues from either cKO or WT mice and 
analyzed for PRR expression by RT-PCR. Figure 39 shows no difference in PRR expression 
in the kidney, heart, liver and lung for WT or cKO mice. In the cKO spleen and thymus, PRR 
expression is slightly decreased compared to WT. This might be explained by the existence of 
several immune cells, including T cells, in the spleen. However, this decrease is small due to 
the presence of other cells, such as B cells, which would still express PRR. Additionally, a 
decrease of PRR expression is observed in the DP+SP pool of thymocytes that are double 
positive (DP) for CD4+ and CD8+ or single positive (SP) CD4+ and CD8+ cells; the DP cells 
are the largest population of T cells in the thymus. The decrease of PRR gene expression in 
the thymus and DP and SP cells alone, indicates that the cKO model is T cell specific. 
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Figure 39: PRR expression in cKO and WT mice.  
RT-PCR mRNA analyses in different organs of WT (white) and cKO (black). DP+SP, thymic pool of double 
positive CD4+ and CD8+ cells and or single positive CD4+ and CD8+ cells.   
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4.4.2. Characterization of lymphocytes in the cKO model 
To determine the effect of conditional PRR deletion on peripheral T cell numbers, spleens 
from 6-8 week old male WT and cKO mice were collected and analyzed by flow cytometry. 
Splenocytes were stained for B cell (CD45R) and T cell (CD3) markers. In addition, 
leucocytes from the blood were isolated and their lymphocyte composition examined. The 
total number of splenocytes was not altered in cKO mice compared to WT mice (data not 
shown). However, a change in the composition of the splenic cells was observed (Figure 40 
A). The proportion of B cells in the spleen was 38 % ± 3 in the WT, compared to 49 % ± 4 in 
cKO mice (B). This was also observed in the blood; 30 % ± 4 in WT compared to in 38 % ± 
10 in cKO mice (C).  
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Figure 40. B and T cells in spleen and blood.  
Splenoyctes and lymphocytes from the blood were stained for CD3 (T cells) and CD45R (B cells) and analyzed 
for their B and T cell composition. (A) Depicted is the typical staining of WT and cKO splenocytes and the 
gating strategy employed for T and B cells. Comparison of the B (B) and T cell (C) composition in WT (white) 
and cKO (black) mice in the spleen (B and C, respectively) and the blood (D and E, respectively). WT n=6, cKO 
n=3, * p>0.05. 
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However, these increases were not significant. A large reduction in the proportion of T cells 
from 22 % ± 1 in WT to 4.9 % ± 0.6 in cKO splenocytes was observed (D). The same was 
found in blood lymphocytes, where T cells were reduced from 20 % ± 1 in WT to 4 % ± 1. in 
cKO (E). These results indicate that deletion of the PRR in T cells results in a decreased T 
cell number of about 80 % in the spleen and in the blood, whilst B cell numbers are not 
significantly changed. 
 
T cells can be further divided into several cellular subsets. The two major types are cytotoxic 
T cells (CD8+ cells) and T helper cells (CD4+ cells), which are characterized by their surface 
expression of the molecules CD4 and CD8. T cells isolated from blood and the spleen as 
described above were subsequently analyzed for their composition of CD4+ and CD8+ cells. 
Figure 41 A shows a typical staining for CD4+ and CD8+ T cells isolated from the spleen. 
Analysis of the proportion of CD4+ and CD8+ cells showed that the percentage of CD4+ cells 
was significantly reduced from 20 % ± 2 in WT, to 2.9 % ± 0.03 in cKO mice (B). CD8+ cells 
were also significantly reduced from 13 % ± 2 in WT, down to 3.1 % ± 0.7 in cKO (C). 
Similar results were obtained for T cells isolated from blood: CD4+ cells WT 15 % ± 1 vs. 
cKO 2.3 % ± 0.7 (D), CD8+ cells WT 9.7 % ± 0.8 vs. cKO 4 % ± 2 (E). In summary, it was 
found that in cKO mice, the percentages of peripheral CD4+ and CD8+ cells decreased by 
approximately 85 % and 70 %, respectively.  
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Figure 41. CD4+ and CD8+ cells are reduced in the spleen and blood of PRR cKO mice. 
Splenoyctes and lymphocytes from the blood were stained for CD4+ and CD8+ markers and analyzed for their T 
cell composition. (A) Depicted is the typical staining of WT and cKO splenocytes, with the gating strategy used 
to identify CD4+ and CD8+ cells. Comparison of the CD4+ and CD8+ cells composition in the spleen (B and C) 
and in blood (D and E).  WT n=7, cKO n=4, * p>0.05. 
 
4.4.3. Characterization of T cell proliferation and apoptosis  
An explanation for the decrease in circulating and splenic T cells could be due to the deletion 
of PRR inhibiting proliferation, or alternatively, increasing T cell death (apoptosis).  
 
To analyze the affect of PRR cKO on T cell proliferation, CD4+ cells were isolated, stained 
with CFSE and cultured for several days. CFSE is a dye, which stains the extracellular 
membrane of cells. When cells undergo division, the dye is diluted and this decrease of CFSE 
positive cells can be measured by flow cytometry. However, it was not possible to purify 
sufficient amounts of CD4+ cells from the cKO mice for this type of experiment, because of 
the low amount of CD4+ cells. So the question of whether PRR deletion affects T cell 
proliferation could not be answered. 
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To investigate if the loss of T cells was due to an enhanced rate of apoptosis, freshly isolated 
splenic T cells were stained for the apoptosis marker, AnnexinV. Figure 42 shows the 
AnnexinV staining for CD4+ and CD8+ splenic T cells. In black, are the WT cells, in red the 
cKO cells. Overlay of the histograms shows almost identical Annexin V staining for CD4+ 
and CD8+ cells from WT and cKO mice. The cKO T cells did not show signs of increased 
numbers of cell death. 
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Figure 42. Apotosis staining of splenic T cells.  
The cells were gated for CD4+ or CD8+ and analysed for Annexin V staining. WT cells are in black, cKO are in 
red.  
 
4.4.4. Characterization of thymocyte maturation 
Another explanation for the observed decrease in mature T cells could be a defect in T cell 
development. T cells mature in the thymus of young mice. During maturation of T cells the 
cells are first negative for the expression of CD4 and CD8 and are therefore called DN 
(double negative) cells. In the next step, they start to express both CD4 and CD8 and are 
therefore DP (double positive) cells. After this stage, the T cells develop into single positive 
cells, expressing either CD4 or CD8.  Thymocytes from 4-6 week old male WT or cKO mice 
were first analyzed for their CD4 and CD8 expression. The proportion and type of thymocytes 
in WT and cKO mice were notably different (Figure 43 A). DN cells were significantly 
elevated from 3.5 % ±0.6 in WT, up to 38 % ±9 in cKO mice (B). DP cells were significantly 
reduced from 79 % ±2 in WT, down to 50 % ±8 in cKO mice (C). This is a relative reduction 
in DP cells of ~40 % and an increase of DN cells of ~90 %.  The proportion of single positive 
(SP) cells in the cKO were unchanged compared to WT (CD4+ cells: WT 15 % ±1, cKO 14 % 
±2 (D); CD8+  cells: WT 2.3 % ±0.4, cKO 5 % ±1.0 (E)). These results indicate that deletion 
of PRR blocks the transition of T cells from DN to DP cells. 
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Figure 43. PRR cKO blocks T cell development.  
A) Typical CD4 and CD8 staining of WT and cKO thymocytes. Comparison of the composition of T cells in the 
thymus of WT and cKO mice: DP (B), DN (C), CD4+ (D) and  CD8+ (E) cells.  WT n=8, cKO n=4, * p>0.05. 
 
DN thymocytes can be further subdivided into DN1-DN4 types. As shown before the deletion 
of the PRR resulted in a dramatic increase of DN cells (Figure 43). Therefore the composition 
of DN cell subsets should be analysed. These are classified by the expression of CD25 and 
CD44 (DN1 = CD25-/CD44+, DN2 = CD25+/CD44+, DN3 = CD25+/CD44-, DN4 = CD25-
/CD44-). To determine which stage PRR deletion blocks T cell development, WT and cKO 
DN cells were isolated and analyzed for their CD25 and CD44 expression (Figure 44 A).  
DN3 cells are significantly elevated from WT 72 % ± 3 to 82 % ± 1 in cKO mice (B). This is 
complemented by a decrease in DN4 cells from 22 % ± 2 in WT, to 14 % ± 1 in cKO (C). As 
the LCK Cre expression only begins at the DN3 stage, the proportion of DN1 (D) and DN2 
(E) cells are unaffected (DN1: WT 5 % ± 2, cKO 3.0 % ± 0.2;  DN2: WT 0.4 % ± 0.04, cKO 
0.6 % ± 0.3). In conclusion, these results indicate that PRR deficiency impairs the DN3-to-
DN4 transition in thymocytes. 
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Figure 44. PRR deficiency blocks transition from DN3 to DN4. 
A) WT and cKO DN thymocytes were stained for the markers CD25 and CD44.  Evaluation of the DN1-4 cell 
composition comparing WT (white) and cKO (black). (B) DN3; (C) DN4; (D) DN1; (E) DN2.  WT n=4 
compared to cKO n=3, * p>0.05 
 
Deletion of the PRR in T cells results in a reduction of T cells. This might be due to a 
developmental block in the DN cells. This data confirm a crucial role for the PRR for T cell 
maturation. 
 
5. Discussion
 
5. Discussion 
The PRR is a single transmembrane receptor that is thought to be important for various 
cellular processes by influencing the activity of the RAS cascade, the WNT/β-catenin 
signalling pathway and vATPase activity. It has been shown that PRR binds renin, LRP6, 
Frizzled and is an accessory protein of vATPase. No structural data is available about the 
soluble part of the PRR and how PRR interacts with its ligands is not clear.  In this thesis, 
several recombinant constructs of the soluble part of the human PRR could be purified. The 
hsPRR (101-257) was found to exist in a concentration and pH dependent monomer/oligomer 
equilibrium, while hsPRR (166-257) was present in a monomer/dimer equilibrium. This 
biochemical characterization and structural analysis will ultimately aid in understanding the 
function of PRR and the relation to the RAS, WNT/β-catenin pathway and vATPase and are 
the basics for further structural and functional investigations. Additionally, using a conditional 
KO the physiological effect of PRR deletion in T cells was investigated in vivo. Specific 
deletion of PRR resulted in a loss of mature T cells in the circulation and in the peripheral 
lymphoid tissue. This reduction was found to be due to a defect in T cell maturation. These 
data help to understand the involvement of the PRR for T cell development.   
 
5.1. Characterization of PRR constructs 
5.1.1. Purification of PRR constructs 
For structural analysis soluble protein is needed in milligram amounts. Therefore a bacterial 
expression system to obtain sufficient amount of recombinant protein was used. The 
purification protocol for the hsPRR (170-303), hsPRR (101-257) and hsPRR (166-257) was 
established and optimized. These soluble constructs are now the basis for further 
characterization, structural studies and cellular assays.  
 
The PRR was in most conditions insoluble. One explanation for this could be that the correct 
folding of PRR depends on the eukaryotic folding machinery. It is known that many proteins 
require molecular chaperones to fold efficiently 157. During the folding procedure partially 
folded states may become transiently populated as kinetically trapped species. Partially folded 
or misfolded states tend to aggregate in a concentration-dependent manner. This is due to the 
fact that these forms typically expose hydrophobic amino-acid residues and regions of 
unstructured polypeptide backbone to the solvent 157. To overcome this problem it would be 
of interest to switch the expression system to an eukaryotic system. Different expression 
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systems in eukaryotic cells for PRR were already published. Several groups expressed full-
length and the soluble part of PRR in the baculovirus expression system 158, 159. Both 
recombinant proteins bound renin or prorenin and facilitated the conversion of 
angiotensinogen. A different approach was to over-express the full-length PRR and PRR 
without the cytoplasmic domain in the fat body and the soluble PRR in the hemolymph of 
silkworm larvae 160-162. These proteins bound to renin and prorenin, but all of these trials 
resulted in low amounts of protein that was never in the milligram range needed for 
crystallization trials. 
 
A second explanation could be that the PRR needs for its correct folding, additional binding 
partners 163. If a binding partner is missing, possible hydrophobic surface patches involved in 
the binding are exposed and could trigger aggregation.  Co-expression of a binding partner 
often improves the solubility of proteins 153. Because of the membrane localization of 
vATPase only subunits of the V0 domain are likely to interact with the extracellular part of the 
PRR 68. Additionally, the PRR could need its transmembrane region for correct folding, but 
this is in contrast to the published eukaryotic expression systems where expression of the 
extracellular part of the PRR was possible in low amounts 160-162.     
 
Stably folded, globular domains of proteins are more likely to be solubly expressed 153. So 
another possibility is that the PRR has large unordered regions in the extracellular region that 
reduce its solubility when over-expressed in E.coli. The secondary structure prediction (see 
Appendix) predicts approximately ~40% alpha helices and ~10% beta strand for the full 
length PRR. Accordingly, ~50% of the protein is predicted to be not structured or to form 
loop regions. It was hypothesized that introduction of mutations that are supposed to reduce 
the surface entropy of the protein, which is usually beneficial for crystallization, might also 
improve the solubility of proteins 152. But the only approach to obtain soluble protein from 
E.coli, was to modify the constructs by cutting flexible loops or predicted disordered regions.  
 
5.1.2. Binding to renin and prorenin 
The binding site for renin or prorenin is thought to be located in the extracellular domain, 
given that renin and prorenin are found almost exclusively in the circulation 1. Therefore, 
soluble PRR is expected to bind renin or prorenin.  In the GST pull-down experiments no 
binding to renin or prorenin was observed for the purified constructs. Also using analytical 
ultracentrifugation binding-assay with hsPRR (166-257), no binding to renin was observed. 
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This was not surprising as hsPRR (166-257) covers the same amino acid sequence as hsPRR 
(101-257).  
 
There are several possibilities to explain this lack of binding to renin and prorenin. Firstly, the 
GST pull-down experiments could be negatively influenced by the presence of the 26 kDa 
GST tag. The GST tag is N-terminally linked to PRR and could sterically inhibit binding to 
the ligands. Additionally, placing the tag to the C-terminus might prevent tag interference. 
Nevertheless, this possibility only accounts for the GST pulldown-assay.  In the analytical 
ultracentrifugation experiments, no GST was linked to the PRR. This experiment showed also 
no binding of renin to the truncated PRR, suggesting that the GST tag was not the reason for 
the lack of renin binding.    
 
Some binding affinities, especially for protein-protein interactions involved in signal 
transduction processes or for cell surface receptors, are described to be rather low in the 
micromolar range. This is often described for functions that require the interaction to be 
transient 164. An alternative explanation for the lack of binding is therefore that the affinity of 
renin and prorenin to the truncated PRR constructs is to low and the ligands are lost during the 
experimental GST pull-down protocol. But this explanation contrasts the already published 
binding affinities of renin and prorenin to the PRR that are in the low nanomolar range. 
Batenburg et al and Nabi et al published almost identical Kd values for renin/PRR binding 
with a Kd of 20 nM, while prorenin bound with a Kd of 7 nM and 8 nM, respectivley to the 
PRR 40, 165. Additionally, low binding affinities should be detectable with analytical 
ultracentrifugation. 
 
Another possible reason for the lack of binding might be that the binding site for renin is 
disrupted. This would happen if the binding site for renin or prorenin is localized in the N-
terminal region (amino acid 1-100) of the extracellular part of PRR. Alternatively, only parts 
of the N-terminal region are involved in binding and are needed to form the binding interface. 
But not only might the N-terminal region be missing for binding to renin or prorenin. It is also 
possible that the extracellular domain together with the transmembrane domain of PRR is 
needed to display full functional binding. This was first described by Du et al. who showed 
that the purified full-length PRR displayed a higher binding affinity to renin (Kd 46 nM) then 
a PRR variant lacking the transmembrane and intracellular domain. The extracellular PRR 
was found to loose its binding affinity after purification, but this could be recovered by 
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addition of microsomes 160. This study suggests that the transmembrane region stabilizes the 
extracellular domain of PRR. The lack of the transmembrane region in the purified constructs 
might weaken the affinity of PRR to renin. 
 
Still another explanation is that the PRR in fact does not bind to renin or prorenin. PRR/renin 
or prorenin interaction was confirmed in cellular assays with radiolabeled renin in human 
mesangial cells 1. Additional studies showed binding of renin to rat smooth muscle cells 
overexpressing the human PRR 40. However, it is likely that the major PRR function is not on 
the RAS. It has already been questioned in the interpretation of PRR binding studies whether 
the affinity of PRR to renin or prorenin is sufficient to bind to renin or prorenin under 
physiological conditions 65. Renin and prorenin are usually found in picomolar levels in the 
circulation and this makes activation of the RAS by binding of renin and prorenin to the PRR 
in vivo implausible, as renin and prorenin could not quantitatively bind to PRR. Higher 
prorenin levels might occur at sites of prorenin expression, but whether its concentration is 
high enough to bind to PRR is not known 65. Additional evidence against an interaction in 
vivo came from Batenburg et al showing that direct renin and prorenin induced effects via the 
PRR require renin and prorenin concentrations far above the levels found in vivo. They 
concluded that renin and prorenin interaction with PRR is unlikely to take place in non-renin 
synthesizing organs 166. Recently, Cruciat et al showed that the PRR functions in a renin 
independent way by mediating WNT/β-catenin signalling 17. Deletion of PRR results in early 
lethality and since the RAS system is not required for survival at this stage 14, this points to 
renin and prorenin independent function of PRR 11.  Thus, PRR seems to be more likely 
involved in acidification and WNT/β-catenin signalling, rather then in the RAS. 
 
5.1.3. Oligomerization of PRR proteins 
A surprising finding from this thesis was that hsPRR (101-257) and hsPRR (166-257) had 
different oligomerization properties. The hsPRR (101-257) was in a monomer/oligomer 
equilibrium and the hsPRR (166-257) in a monomer/dimer equilibrium. This change in 
oligomerization of hsPRR (101-257) occurred at almost physiological pH between pH 7.5 and 
pH 8. Therefore, a histidine might be involved in this process, whose imidazol ring has a pKa 
of 6 167.  By truncating hsPRR (101-257) to produce hsPRR (166-257), the oligomer was no 
longer observed. In the additional 65 amino acids of the hsPRR (101-257), only one histidine 
is found at position 114 (Figure 45). This histidine is conserved among all species, pointing to 
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an important role of this residue in the function of PRR. Mutating this histidine, might result 
in the breakdown of the oligomer. 
101 114
166
257
 
 
Figure 45: Amino acid alignment of the hsPRR (101-257) with different species (mouse, rat, danio/ 
zebrafish and xenopus/frog.  
100% conserved residues are boxed in light blue, 80% conserved residues are boxed in light green and 60% 
conserved residues are in light yellow boxes. Histidines are highlighted in red.  
 
It is possible that the full-length PRR has the same pH- and concentration-dependent 
monomer/oligomer equilibrium. Schefe et al showed that the full-length PRR could be co-
immunoprecipitated with itself 8.  They concluded that the PRR assemblees as a homodimer, 
but the formation of larger oligomers would also be compatible with their results.  For the full 
length PRR proteins, oligomerization would be mediated by the extracellular domain of the 
PRR, but could still influence via the transmembrane region and the short intracellular domain 
an interaction with the intracellular V1 or the transmembrane V0 domain of the vATPase. The 
RALS analysis of hsPRR (101-257) indicates that it assembles as pentamer or hexamer.  
Interestingly, the vATPase displays as well a hexameric structure. The A and B subunit of the 
V1 domain are arranged as a heterohexamer and also the proteolipid of the V0 domain is 
described as a hexameric ring 68. The soluble part of the PRR would be localized at the 
extracellular part of the plasmamembrane or in intracellular vesicles. An interaction of the 
soluble PRR with the intracellular V1 domain of the vATPase, is therefore not possible, but an 
interaction with the transmembrane proteolipid ring of the V0 domain would be feasible. 
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Therefore a hypothetical link of the PRR oligomer and the vATPase hexamer is possible and 
might play a role for binding and function. 
  
The pH dependent oligomerization points towards a functional implication of pH for the role 
of PRR. As already described, the vATPase is a proton pump required for acidification of 
intracellular compartments or extracellular fluid 66. How the vATPase senses pH is not fully 
understood. The shift of hsPRR (101-257) from a monomer to monomer/oligomer equilibrium 
occurred between pH 7.5 and pH 8 at basic conditions. This somehow contrast with the fact 
that vATPase is only mediating acidification (pH below 7), but for the full length PRR the pH 
dependent oligomerization could occur at lower pH. Furthermore, other factors are described 
to influence vATPase activity in a pH dependent manner. It was already shown that Arf6 and 
ARNO partially co-localize with vATPase in the apical endosomes in proximal tubules in the 
kidney 168. Both proteins were recruited in a pH dependent fashion from the cytosol to 
endosomes. Arf6 interacts with the c subunit, whereas ARNO interacts with the a2 isoform of 
vATPase. Inhibition of the vATPase/ARNO/Arf6 interactions inhibited early endocytosis. 
This indicates that Arf6 and ARNO play an important role in the pH dependent regulation of 
receptor-mediated endocytosis 169. The functional difference for the hsPRR (101-257) and 
hsPRR (166-257) and the pH dependent oligomerization will be investigated in the future. 
 
5.1.4. Structural investigations of the PRR proteins  
Structural information will broaden the understanding of the function of the PRR. 
Crystallization is still a process that is not predictable. Some factors can influence 
crystallizability of proteins and some decrease the likelihood of forming crystal contacts 170. 
In numerous trials, crystallization of the soluble PRR constructs was not successful, but I was 
able to obtain significant insights into the biochemical behaviour of hsPRR (101-257) and 
hsPRR (166-257) were obtained, which may provide explanations for this phenomena. 
 
The hsPRR (101-257) is present in solution in a monomer/oligomer equilibrium. Such an 
equilibrium is not favourable for crystal formation, as two or more species are present in 
solution 170. During initial screens, this pH and concentration dependent monomer/oligomer 
equilibrium was not known. Therefore most of the screens were performed at a pH of 7.5 and 
below. From the biochemical characterization, it is now clear that the hsPRR (101-257) 
precipitates at pH 6.5 and below, which is close to the theoretical pI value of 4.9 of the PRR. 
At this point the hsPRR (101-257) has the lowest solubility in solution and precipitates. As 
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discussed previously, it was found that the hsPRR (101-257) is present as a monomer at pH 8 
and above. Thus, future crystallization trials for hsPRR (101-257) will be optimized at these 
higher pH, where hsPRR (101-257) is predominantly monomeric, increasing the likelihood of 
the crystal formation. 
 
During purification of hsPRR (166-257), it appeared that this protein would be ideal for 
crystallization trials. In contrast to hsPRR (101-257), the protein could be concentrated up to 
90 mg/ml without precipitation. Additionally, the purity of this protein was above 95 % and 
the samples seemed to be homogenous by gel filtration. However, it turned out that hsPRR 
(166-257) was present in solution as a monomer/dimer equilibrium. Unlike hsPRR (101-257), 
the equilibrium for the hsPRR (166-257) could not be shifted to a monomeric protein by 
increasing the pH to 8 and above. Whether this equilibrium might be influenced by changing 
the buffer conditions (e.g, salt or pH) is still under investigation. This information should be 
used for the design of following crystal screens.  
 
It appeared that hsPRR (166-257) was not stable over the time at 20 °C and this may affect 
crystallization. During the sedimentation equilibrium run a loss of the UV signal was 
observed (Figure 46). The difference in the absorbance signal after 44 h and 68 h at the radial 
distance of 6 cm is not compensated at the radial distance at 6.1 cm.  
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Figure 46. Sedimentation equilibrium analysis of hsPRR (166-257) at 2mg/ml. 
Absorbance scans were taken after the sample reached equilibrium after 44 h at 20,000 (green) and after 68h at 
35,000 (red) rpm. The capped blue line indicates the difference in OD signal at radial position 6 cm that was not 
observed at radial position 6.1 cm. 
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The area under the curve reflects the amount of protein in the sample and this area decreases 
over the time. This was especially observed at higher concentrations, 2mg/ml and above, 
whilst this was not seen at concentrations below 1mg/ml.  This can be explained by the slow 
precipitation of the protein at 20°C. 
 
In NMR measurements, the HSQC spectrum for the hsPRR (166-257) revealed that the 
protein was folded but the dispersion of the resonances was not good and several resonances 
were overlapping. The monomer/dimer equilibrium might explain why the spectrum was not 
useful. The sample is in constant exchange and therefore the peaks seem to smear 156. Since 
assignments are crucial for structure determination and this was impossible, NMR 
experiments were not continued. Another possibility would be to test the longer construct, the 
hsPRR (101-257), in NMR spectroscopy. 18 kDa are still in the size range for NMR structure 
determination, although the low amount of aromatic residues and the high alpha helical 
composition of the hsPRR (101-257) might still be problematic. An advantage of this sample 
would be the possibility to perform measurements at pH 8 where the protein is a monomer. A 
homogenous sample might ameliorate the quality of the spectra. 
 
5.2. Conditional deletion of PRR in T cells  
5.2.1. PRR cKO causes a decrease in T cell numbers due to a block in  
            development 
One hypothesis of this thesis was that the deletion of PRR in T cells would result in a 
phenotype similar to a conditional deletion of β-catenin in T cells. This is based on recent 
studies showing PRR to be essential for Wnt/ β-catenin signalling 17. Deletion of β-catenin 
resulted in an impaired T cell development in the thymus 120. A comparison of both models 
would help to understand the role of PRR for Wnt/ β-catenin signalling. In both models a cre 
recombinase under the control of the Lck promoter was used. The cre expression starts at the 
DN3 stage during T cell development.  
 
The PRR knockout model showed a reduced number of T cells in the spleen, whereas the 
number of B cells rose only marginally. Interestingly, a similar reduction of T cells in the 
spleen for the PRR cKO and for the T cell specific β-catenin KO is described 120. For the PRR 
model, both CD4+ and CD8+ cells were affected, which was also shown for the β-catenin 
deletion model. Two possible explanations for this decrease in T cell numbers might account 
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for this: a reduction in cell proliferation or a block in development. In the β-catenin KO, Xu et 
al described that mature KO T cells had a decreased proliferation rate 120. In the present study, 
this was not possible to determine as not enough T cells could be isolated from PRR cKO 
mice for proliferation assays. However, a defect in the maturation in the thymus was shown, 
at the DN-DP stage. The DN cells usually make only a small minority of about 5 % in WT 
mice, but in the PRR cKO mice this number of DN cells was increased to ~37 %, 
corresponding with a decrease in DP cells from 80 % to 50 %. These changes in DN/DP cell 
proportions are more dramatic in the PRR cKO then those described for the β-catenin 
phenotype, where the authors only describe an increase in DN cells from 3% in WT mice to 8 
% in the cKO 120. In consequence, the phenotype in mature T cells in the periphery is similar 
to the one observed in β-catenin KO animals, but the closer analysis of the development in the 
thymus shows some differences and are even more dramatic in the PRR cKO model. A role 
for the PRR for Wnt/β-catenin signalling can not be excluded.  
 
5.2.2. Block in the transition from DN3-DN4 might be due to PRR 
affecting pre-TCR signalling    
The mature T cells are decreased in the PRR cKO model and it seems that these T cells have a 
developmental block in the DN stage in the thymus. The recombinase expression starts at the 
DN3 stage in the thymus, so therefore one explanation for the decrease in the PRR cKO T cell 
could be that the T cells die as soon as the PRR is deleted. But this is in contrast to the 
remaining mature T cells and the DP cells that are still able to develop into T cells.  
 
The phenotype of the T cell specific PRR cKO model is in many ways similar to the β-catenin 
KO phenotype. By deleting the PRR in T cells a decrease in the percentage of DN4 cells and 
an increase of DN3 cells was observed. The same was true for the β-catenin deletion in T cells 
120. The authors favour the explanation that the deletion of β-catenin affects pre-TCR 
signalling, that in turn leads to impaired T cell differentiation. They propose that the β-
selection checkpoint at the DN3 cell stage is influenced by WNT/β-catenin signalling and, as 
a result, the cells cannot proliferate and further develop at this stage. As PRR is shown to be 
important for WNT signalling 17, it is possible that PRR deletion in T cells affects T cell 
development in a similar manner. 
  
Another link for the involvement of the pre-TCR was shown previously. The pre-TCR is 
down-regulated by constitutive internalization and degradaded in lysosomes 171. This might be 
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required for the development of T cells and their function. This phenomenon is only described 
for the αβTCR 171.  Since degradation of the pre-TCR occurs in lysosomes it is likely to be  
vATPase dependent. Another possibility is that this degradation process and the 
internalization of the pre-TCR is regulated by WNT/β-catenin signalling. By deletion of the 
PRR, downregulation might be interrupted and T cell development might be disturbed. This 
could also explain the block at the DN stage since the pre TCR expression starts in the 
beginning of the DN3 stadium. 
 
5.2.3. Role of the vATPase in T cell development 
It has also been recently shown that PRR is important for vATPase activity 87, 92.  Conditional 
KO in other cell types, like cardiomyocytes 87 and podocytes 91, 92, have shown a disturbance 
in vacuolar pH as a result of reduced vATPase activity. Defective autophagy is also described 
in these PRR cKO models 87, 91, 92.  Currently, no conditional KO for any subunits of the 
vATPase in hematopoetic cells or T lymphocytes has been performed, and so no direct 
comparison between PRR cKO can be made.  The vATPase is a crucial factor for autophagy, 
a conserved intracellular protein degradation process, depending on the acidification of 
intracellular vesicles.  Autophagy is also an important process for T cell development and 
function. In ATG5 deficient mice (a protein involved in autophagy), T cells fully matured, but 
the number of peripheral CD4+ and CD8+ cells is reduced. These cells show increased cell 
death and have a proliferation defect after TCR stimulation, indicating that ATG5 is important 
for survival and proliferation of T cells 131.  This is in contrast to another autophagy associated 
KO model. Beclin-1 deficient Rag 1−/− chimeras have a dramatically reduced number of 
thymocytes, but the peripheral T cell compartment is unchanged. Proliferation of peripheral T 
cells is not affected, but they showed a reduced number of autophagosomes.  The authors of 
this study conclude that Beclin-1 is required for maintenance of undifferentiated/early 
lymphocyte progenitor populations and plays a role in the development of T cells 172. The 
described phenotypes for these models are not directly comparable to the PRR cKO 
phenotype, but indicate a role for autophagy in early T cell development and function. This is 
turn suggests that PRR via its vATPase function might play a role in T cell maturation by 
affecting autophagy.  
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5.2.4. PRR deletion decreases but does not completely reduce T cells 
Deletion of the PRR in T cells reduces mature T cells down to 5 %, but does not result in a 
complete lack of T cells. There are several reasons to explain the existence of the remaining T 
cells.   
 
One explanation for the surviving 5 % of the T cells is that the recombination of the cre-
recombinase is not a 100 % efficient and the floxed exon 2 of the PRR is not deleted in all T 
cells. For thymocytes a complete deletion of the PRR exon 2 (as well as for DN and for 
DP/SP cells, data not shown) was seen, whereas in the spleen the full-length PRR was still 
apparent. This could be due to the cellular composition of the spleen. The spleen harbours not 
only T cell, but also B cells and other immune cells that still express the PRR. Another aspect 
is the loss in T cells, while they T cells are only present in low amount in the spleen it is 
difficult to determine the excised PRR. But the data from the thymus show a complete 
recombination there. The Lck promoter is known to be active only at early stages of T cell 
development 173 and is expressed only transiently in the thymus 174. Therefore the 
recombinase has only limited time to delete the floxed gene of interest. Thus, some T cell 
might escape recombination in the thymus, mature and are found then in the periphery. The 
amount of not excised T cells in the thymus might be to low to be detected, but as soon as the 
mature T cells are in the circulation they proliferate and represent the 5 % of surviving T 
cells. The T cells in the periphery need further experiments to determine their background. 
 
Another possibility is that the 5 % of surviving T cells are PRR deleted and still are able to 
develop into mature T cells. If this is the case, it would be interesting to analyze if they are 
functional and can be activated by TCR stimulus. A different explanation would be that γδ T 
cells are now found in the circulation. T cells are characterized by their TCR which is in most 
T cells the αβ TCR. But a small subset expresses a γδ TCR on their surface 121. This subset 
should not be affected by the PRR deletion, because they have a different developmental 
pathway and are not affected by the Lck cre expression. It could be that the main T cell 
subset, the αβ T cells, are completely decreased because of PRR deletion and the suriving 
cells are now only γδ T cells.  A further suggestion is that an alternative signalling pathway 
might be involved in the regulation of T cell development. If the PRR interferes with WNT 
/β-catenin pathway and WNT /β-catenin signalling is disregulated in this model, another 
pathway might take over the function. Notch signalling is as well known to be involved on T 
cell development and could play a role 175. 
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5.3. Outlook and perspectives 
Since the PRR was originally described as a component of the RAS and it was shown that 
binding of renin or prorenin to the PRR resulted in an activation or enhancement of the 
angiotensinogen cleavage 1, the PRR has been postulated as a potential drug target . The first 
putative blocker (HRP) of the PRR was described by Ichihara et al 59. Beneficial 
cardiovascular and renal effects for HRP were described in diverse animal models, like 
spontaneous hypertensive rats and diabetic models 60, 61. Here, HRP and PRR blockade had an 
organ protective effect. This was already controversially discussed since a variety of other 
models could not confirm these beneficial effects 43, 63, 176.  With the finding that the PRR is 
involved in WNT signalling and might be a regulator of the function of vATPase 17, the PRR 
as a drug target has to be seen sceptical. Additionally, deletion of the PRR in cardiomyocytes 
and podocytes resulted in cellular death and early mortality 87, 91, 92. cKO of the PRR in T cells 
resulted in impaired maturation. The PRR is present in all cells and tissues and seems to have 
fundamental functions for cellular development and function, therefore inhibition of the PRR 
seems to be critical.  
 
The function of the soluble PRR is still unknown, but it was shown that the PRR is processed 
by furin 4. This soluble protein is shedded into the medium of cultured cells and might play an 
important role in the circulation 6. The function of the soluble PRR is still unknown, but could 
be analyzed with an ELISA. The hsPRR (101-257) led to the development of an ELISA to 
detect soluble PRR in human serum.  This ELISA measures reproducibly the soluble PRR in 
the range of 100 pg/ml and 30 ng/ml (personal communication G. Nguyen, Paris). Currently, 
various pathologic and healthy patient groups are analyzed for differences in the soluble PRR 
levels. Thus, with this ELISA it can be analyzed if the soluble PRR is linked to diseases, like 
cardiovascular disease.  
 
A focus for the ongoing work is to functionally characterize the PRR constructs. All human 
PRR constructs produced in this work are not binding to renin or prorenin, so they do not 
seem to be involved in the function of the RAS. Nevertheless, several implications for the 
PRR are described. It was shown that the PRR influences Wnt/β-catenin signalling 17 and 
might play a role in vATPase mediated acidification 109, 110. The next aim would be to find a 
cellular assay to test the functionality of the PRR proteins for Wnt/β-catenin signalling and 
acidification. The effect of the PRR proteins in cell culture should be investigated. To analyze 
the role of the soluble PRR, the purified PRR constructs can be used for Wnt/β-catenin 
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reporter gene assays. To analyze in vitro acidification, it could be determined if the PRR 
constructs influence acidification in lysosomes and intracellular vesicles.  
 
One possibility to gain more insights into the role of the PRR is a rescue of the cKO 
phenotype. As the β-catenin deletion showed a similar phenotype as the PRR deletion, a 
rescue of the PRR cKO with a constitutive active β-catenin would be of interest. β-catenin can 
be expressed in transgenic animals as a stabilized active mutant.  When over-expressed in 
immature thymocytes, T cells develop, but they lack the αβ TCR and develop in the absence 
of pre-TCR signaling and TCR selection 177. This points to the fact that the WNT pathway 
needs to be in homeostasis.  Since reduction and over-expression of components of the 
pathway leads to a deregulation of the system, a rescue strategy with a constitutive active β-
catenin could probably not answer the question if the PRR is involved in the WNT pathway. 
Another option would be the rescue of the cKO PRR T cell model with the soluble 
recombinant proteins of PRR. By purifying the hsPRR (101-257) and hsPRR (166-257) in 
sufficient amount and quality and solving the structure, this could be used as a tool to 
investigate its function in vivo. It would be interesting to examine if the recombinant PRR 
constructs are able to rescue T cell development in cKO animals.  If rescue is possible it could 
be analyzed if this mechanism is due to activation of Wnt/ β-catenin signalling or if impaired 
autophagy and acidification are involved. An analysis of the effect of the soluble PRR on T 
cell culture could help to understand the effect of the PRR on T cell function. Also for other in 
vitro and in vivo models this might be a useful tool for the future. 
 
This thesis showed that truncated versions of the human PRR are in a monomer/oligomer 
equilibrium that could have functional implications. The recombinant PRR proteins could be 
the basis for future investigations to analyse the structure of PRR and carry out a detailed 
structure/ function analysis. These constructs could now help to understand the role of the 
soluble PRR in vivo. In addition the deletion of the PRR in T cells resulted in impaired 
thymocyte development pointing to an important role for the PRR and cell maturation. 
Further understanding of the role of PRR for cellular function and development is needed.  
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6. Zusammenfassung 
Der (Pro)Renin Rezeptor (PRR) ist ein evolutionär hoch konservierter 
Transmembranrezeptor, der ursprünglich beschrieben wurde Renin und Prorenin zu binden. 
Durch Bindung an Renin und Prorenin ist der PRR in der Lage, die Aktivität des Renin-
Angiotensin-Systems (RAS) zu beeinflussen und MAP-Kinase-Signaltransduktion zu 
induzieren. Es wurde bereits gezeigt, dass der verkürzte Transmembranteil des PRR assoziiert 
ist mit der vakuolären H+-ATPase (vATPase), welche wichtig für die Azidifizierung zellulärer 
Organellen ist. Kürzlich wurde eine neue Funktion des PRR für den WNT/β-catenin 
Signalweg beschrieben. Hier dient der PRR als Verbindungsglied zwischen den WNT 
Rezeptoren und der vATPase. Die genauen Mechanismen der Funktionen des PRR sind 
bislang noch nicht verstanden, aber es wird angenommen, dass der PRR in die Regulation 
verschiedenster zellulärer Mechanismen involviert ist. 
 
Es gibt bis jetzt keine biochemische Charakterisierung oder strukturelle Analyse über diesen 
verkürzten Teil des PRR. Um die Funktion des PRR besser zu verstehen, wurden in der 
vorliegenden Arbeit strukturelle Studien mit verschiedenen verkürzten Konstrukten des 
extrazellulären Teils des PRR durchgeführt. Alle PRR Konstrukte (hsPRR (170-303), hsPRR 
(101-257) und hsPRR (166-257)) zeigten eine alpha-helikale Faltung und konnten nicht an 
Renin oder Prorenin binden. Des Weiteren wurde die oligomere Zusammensetzung dieser 
Konstrukte untersucht. Der hsPRR (101-257) liegt in einem Konzentrations- und pH-
abhängigen Monomer-/Oligomerequilibrium vor, während der hsPRR (166-257) als 
Monomer/Dimerequilibrium vorkommt. Diese Daten bilden die Grundlage für weitere 
strukturelle und funktionelle Untersuchungen. 
 
Konditionelle KO Mäuse sind eine exzellente Methode, um die physiologische Rolle des PRR 
in vivo zu untersuchen. Eines der wichtigsten Proteine des Wnt/β-catenin 
Signaltransduktionsweges, β-catenin, ist fundamental für die T-Zell Entwicklung. Aus diesem 
Grund wurde untersucht, ob die Deletion des PRR in T-Zellen ebenfalls zu einem Verlust von 
T-Zellen führt. Des Weiteren wurde analysiert, ob es zu einer Entwicklungsstörung im 
Thymus kommt. Die Ergebnisse zeigen, dass der PRR wichtig für eine vollständige T-
Zellentwicklung ist und unterstützen die Hypothese, dass der PRR eine Rolle für Wnt/β-
catenin Singaltransduktion in T-Zellen spielt. 
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hs 1   -MAVFVVLLA -LVAGVLGNE FSILKSPGSV VFRNGNWPIP GERIPDVAAL SMGFSVKEDL  58   
mm  1   -MAVLVVLLF FLVAGALGNE FSILRSPGSV VFRNGNWPIP GDRIPDVAAL SMGFSVKEDL  59   
rn    1   -MAVLVVLLS SLVSSALANE FSILRSPGSV VFRNGNWPIP GDRIPDVAAL SMGFSVKEDL  59   
dr    1   -MNAVFALIG -LLSGVLGDS LTVLRSPQYV TFRDEQWPIS GEKIPDLVAL TMGFSVREDL  58   
xt    1   ---MLRLALA ALVLADRSAV INIIGSNVCP IYKEAEDALP WRRIAKRYLG LHVMSVNEDL  57   
dm    1   MLRVFVIFSL FIAAINASGE FTVLNRPKAI SFK-GNDALE SHYVGDVLYA SMGNAVSGDT  59   
 
 
 
hs   59  SWPGLAVGNL FHRPRATVMV MVKGVNKLAL PPGSVISYPL ENAVPFSLDS VANSIHSLFS  118  
mm   60  SWPGLAVGNL FHRPRATIMV MVKGVDKLAL PAGSVISYPL ENAVPFSLDS VANSIHSLFS  119  
rn   60  SWPGLAVGNL FHRPRATIMV TVKGVDKLAL PTGSVISYPL ENAVPFSLDS VANSIHSLFS  119  
dr   59  DWPGLAAGSL FQRPRANALI VVRGIDSLDF PKN-VSSYPL ENPVPFTLDS VANTVHTLFA  117  
xt   58  SWSGLGVGNL FQRPRATVLV TVTGVNKLPL SGN-GISYPV ENAVPYSVDS VVNSIHSVFS  116  
dm   60  NWNGLTINDP FNLAKGVILV HVQGIGHVTT AGN-VKTYEL TGSG---TDA SLNALAAELE  115  
 
 
 
hs   119 EETPVVLQLA PSEERVYMVG KANSVFEDLS VTLRQLRNRL FQENSVLSSL PLNSLSRNNE  178  
mm   120 EETPVVLQLA PSEERVYMVG KANSVFEDLS VTLRQLRNRL FQENSLLNSL PLNSLSRNNE  179  
rn   120 EETPVVLQLA PSEERVYMVG KANSVFEDLS VTLRQLRNRL FQENSVLNSL PLNSLSRNNE  179  
dr   118 DSTPVVLQLA PSEERLYMMG MANTVFEDLP VTLQQIRGRL SQDGSVLTSL PLVSLSRNNE  177  
xt   117 EEMPVVLQLA PIEERVYMVG KANTVFEDLA VTLRQLRTRL EQDNSVIQSL PVSSLYRNDE  176  
dm   116 AANEPVCDIN ---------- -----FEQFD DGVQAWKSCF G-DFEAPAAK PTKHLNPS--  157  
 
 
 
hs   179 VDLLFLSELQ VLHDISSLLS RHKHLAKDHS PDLYSLELAG LDEIGKRYGE DSEQFRDASK  238  
mm   180 VDLLFLSELQ VLHDISSLLS RHKHLAKDHS PDLYSLELAG LDELGKRYGE DSEQFRDASK  239  
rn   180 VDLLFLSELQ VLHDISSLLS RHKHLAKDHS PDLYSLELAG LDELGKRYGE DSEQFRDASR  239  
dr   178 ADLLFLSEVQ VLYDISALLQ KHKHLAKDPA PDLYSLELAG LEEIVRRYGT DSPQYTDAIR  237  
xt   177 TDRLFLSELQ VLQDIVTLLS GHKHLAKDNV PDVYSLELTG LEEIKKRYGE DSAQFKDAVQ  236  
dm   157 ---LHTADKQ FLQEVGFINS AADHLAEMAK PSNVLMLRVS VDGVAKAHGE KSVAVEEANK  214  
 
 
 
hs   239 ILVDALQKFA DDMYSLYGGN AVVELVTVKS FDTSLIRKTR TILEAKQAKN PASPYNLAYK  298  
mm   240 ILVDALQKFA DDMYSLYGGN AVVELVTVKS FDTSLVRKSR TILEAKQE-N TQSPYNLAYK  298  
rn   240 ILVDALQKFA DDMYSLYGGN AVVELVTVKS FDTSLVRKSR TILETKQE-N TQSPYNLAYK  298  
dr   238 ILTIALQKFA DDVSSVYGNN AVVEVVTVKT FEVPLTRKSR SILESKQMSN PGSPYNLAYK  297  
xt   237 ILSDSLEKFA DDMYSFYGGN AIVEVVTVES FEIPLVRRSR SILASEAISN PGSPYNLAYQ  296  
dm   215 LLSAAISRLL AASQ---KSS DSVLFVQTTE KDVAASRAKR DTIAASTT-- --NPYNLAVY  267  
 
 
 
hs    299 YNFEYSVVFN MVLWIMIALA LAVIITSYNI WNMDPGYDSI IYRMTNQKIR MD- 350  
mm    299 YNLEYSVVFN LVLWIMIGLA LAVIITSYNI WNMDPGYDSI IYRMTNQKIR ID- 350  
rn    299 YNLEYSVVFN LVLWIMTGLA LAVIITSYNI WNMDPGYDSI IYRMTNQKIR MD- 350  
dr    298 YNFDYAVIFN IVLWLMIVLA LAVIAISYNL WNMDPGYDSI IYRMTNQKIR LD- 349  
xt    297 YNFDYSVIFN IILWIMIGLA LAVIAISYNL WNMDPGYDSI IYRMTNQKIR MD- 348  
dm    268 YGSDYPVIFN IILWFMVVFG LSLLAICYAI AAMDPGRDSI IYRMTSTRIK KDN 320  
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Figure 47. Alignment of PRR 
Protein sequences of Homo sapiens (hs) (Swiss Prot Acession No. O75787), Mus musculus (mm) (Q9CYN9), 
rattus norvegicus (rn) (Q6AXS4), Danio rerio (dr) (Q6PBY2), Xenopus tropicalis (xt)(Q5M8F1) and 
Drosophila melanogaster (dm) (Q 9VHG4) PRR were aligned using ClustalW 136. Residues with a conservation 
of greater than 70% are color-coded (L, V, I, M in green; W in light green; S, P, Q, T in grey; N in light grey; A, 
Y, F in cyan; R, K in blue; G in yellow; E, D in red; H in magenta). The predicted secondary structure of human 
PRR (Jpred 137) is shown on top with α-helices indicated as red barrels and β-strands as yellow arrows.   
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A  Absorbance 
a.u. arbitrary units 
ACE angiotensin-converting-enzyme 
AIM autoinduction medium 
Amp Ampicillin 
ANGI Angiotensin I 
ANGII Angiotensin II 
AOGEN angiotensinogen 
AT1R angiotensin II type 1 receptor 
AUC analytical ultracentrifugation 
bp Base pair 
Cam Chloramphenicol 
Carb Carbenecillin 
CD circular dichroism 
Da Dalton 
DNA deoxyribonucleic acid 
dNTP Desoxynukleosidtriphosphate 
DTT  dithiothreitol 
E.coli  Escherichia coli 
ED extracellular domain 
EDTA Ethylenediaminetetraacetic acid 
FCS fetal calf serum 
g Acceleration of gravity 
GSH reduced Gluthathione 
GST Gluthathione-S-transferase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSQC Heteronuclear single quantum coherence 
ID intracellular domain 
IMAC Immobilised metal affinity chromatography 
IPTG isopropyl-1-β-D-thiogalactopyranoside 
Kan Kanamycin 
LB Luria-Bertani media 
M Molar 
MW molecular weight 
NMR Nuclear magnetic resonance 
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OD optical density 
PBS phosphate buffered saline 
PCR Polymerase chain reaction 
PRR (Pro)renin receptor 
RALS right angle light scattering 
RAS renin-angiotensin-system 
RNA Ribonucleic acid 
rpm revolutions per minute 
RT Room temperature 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis
SP signal peptide 
TAE Tris/Acetic acid/EDTA buffer 
TB teriffic broth 
TCR T cell receptor 
TM transmembrane domain 
Tris Tris(hydroxmethyl)aminomethane 
vATPase vacuolar proton ATPase 
WT Wild type 
β-ME beta-Mercaptoethanol 
θ molar ellipticity 
λ wavelength 
 
Amino acid 3- letter code 1-letter code Amino acid 3- letter code 1-letter code 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartate Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamate Glu E Serine Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
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